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Abstract 
 Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder 
whose pathologic hallmark is the presence of neuronal cytoplasmic inclusions (NCIs). In 
approximately 97% of ALS cases, NCIs are found to be TDP-43+. Rho-guanine nucleotide 
exchange factor (RGNEF) has recently been implicated in ALS pathophysiology through its co-
localization and coimmunoprecipitation with TDP-43+. RGNEF has also been shown to harbour 
cytoprotective effects in the N-terminal region and is responsible for the regulation of low 
molecular weight-neurofilament (NFL), intimately involved neural structure, through its 
predicted RNA-binding domain (RBD). This study looked to purify constructs of RGNEF 
through nickel immobilized metal affinity chromatography (Ni-IMAC) and validate the 
previously documented functions of RGNEF ex-vivo. N-terminal constructs of RGNEF tended to 
self-associate into higher order structure and did not display a direct interaction with TDP-43 
through SPR. pMJ5922, an RBD construct, was successfully purified and did demonstrate RNA-
binding ex-vivo, validating maintenance of functionality following purification.  
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Summary for Lay Audience 
 Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurodegenerative 
disorder for which the cause is often unknown. Progressive neurodegeneration is in part caused 
by a combination of maladaptive protein and RNA processing. Typically, proteins involved in 
these defective systems are RNA-binding proteins (RBPs). One such protein is Tar DNA-binding 
protein-43 (TDP-43), whose involvement in ALS pathologic mechanisms leads to its aggregation 
and formation of neuronal cytoplasmic inclusions (NCIs). TDP-43 has been shown to co-localize 
with a secondary protein, Rho-guanine nucleotide exchange factor (RGNEF), in ALS-affected 
cells. Expression of RGNEF within cells typically helps with cell survival and the regulation of 
important structural protein RNA. Association of RGNEF into the NCIs may decrease these 
functions. In this study, segments of RGNEF were purified and tested to determine biophysical 
characteristics and if function could be maintained outside of the cell. Tests showed that with a 
small segment of RGNEF, TDP-43 did not interact directly. This segment of the protein also 
tended to self-associate into larger structures. A second segment of RGNEF did display binding 
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Chapter 1 – Introduction 
1.1 Clinical Relevance of ALS 
1.1.1 History 
Amyotrophic later sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive 
neurodegenerative disease of the motor neurons. Described previously by several prominent 
anatomists and neurologists of the 1800s, the disease was first coined in 1874 by Dr. Jean-Martin 
Charcot based on his series of case studies between 1865 to 18691. His term aptly detailed the 
physiological presentation of ALS: muscle wasting due to decreased electrical input to the 
muscle cell from motor neurons housed within the anterior horn of the spinal cord. Disease 
progression correlates with increased motoneuron (MN) death, causing sclerotic plaque 
formation in the spinal cord, further inhibiting remaining electrical impulses, and increasing 
muscle atrophy.  
1.1.2 Clinical Presentation 
Since 1874 our knowledge of ALS has become increasingly comprehensive. ALS is now 
understood to affect various neuronal populations, including both upper and lower motor neurons 
(UMN and LMN), and occasionally those within the frontal and temporal lobes. UMN 
involvement comprises affliction of corticopontine and corticospinal MNs, with symptomatology 
reflective of difficulties in signal transduction to LMNs. Patients generally display slowed 
activation of the muscles with increased stiffness and spasticity, as well as recovery of the 
Babinski reflex2. LMN involvement afflicts MNs of the spinal cord and brainstem, with patients 
displaying fasciculations of muscle cells directly connected to diseased LMNs in early stages, 
followed by progressive paralysis and atrophy of the muscle cell3. Depending on the populations 
involved and degree of involvement, initial presentation varies and can be classified as one of the 
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following: Primary Lateral Sclerosis (PLS), progressive muscle atrophy (PMA), limb-onset ALS 
with combined involvement, or bulbar-onset ALS (bALS)4. PLS can be defined as “progressive 
UMN dysfunction in the absence of clinical signs of LMN involvement”5. If LMN involvement 
becomes apparent, patients will be diagnosed with ALS. In contrast, patients with PMA initially 
present with signs of solely LMN degeneration and associated muscle atrophy4. Progressive 
signs of UMN involvement render a later diagnosis of ALS, or ALS may be diagnosed post-
mortem via autopsy finding of UMN degeneration. Limb-onset ALS with combined UMN and 
LMN involvement can be thought of as a classic presentation of ALS; patients display symptoms 
of both LMN and UMN degeneration beginning in the extremities and progressing toward the 
body-center4. bALS differs from the aforementioned subtypes as initial signs of disease are 
visualized as dysfunction of the MNs of oropharyngeal musculature, causing dysarthria and 
dysphagia. While 70% of those diagnosed with ALS have spinal-onset subtypes, referring to the 
loss of function beginning in the extremities with an inward progression, 30% are diagnosed with 
bALS6. It has also been noted that the specific neuropathology of bALS may increase the chance 
of cognitive and language deficits related to frontotemporal neuron degeneration, occasionally 
leading to a comorbid diagnosis of frontotemporal lobe dementia (FTLD)6.  
1.1.3 Diagnosis, Epidemiology, and Current Therapeutics  
Apart from genetic sequencing in cases of inherited ALS, diagnostic techniques have 
remained relatively unchanged in recent decades relying heavily on an exclusion-based criteria 
for other possible conditions. As no biomarkers for ALS are currently available for standardized 
laboratory testing, definitive diagnosis can only be made post-mortem via MN biopsy. However, 
common techniques such as laboratory testing, magnetic resonance imaging, cerebrospinal fluid 
analysis, and electrophysiological studies can be used to rule out differential diagnoses with 
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overlapping symptoms. Namely, these can include Myasthenia Gravis, Guillan-Barré Syndrome, 
Lyme Disease, vitamin deficiency, heavy metal poisoning, various neuropathies and myopathies, 
among others4. Patient demographics and history must also be taken into consideration when 
exploring differential diagnoses of ALS.  
ALS has an incidence rate of 2.4-3.0 per 100 000 per annum with a lifetime risk of 1:350 
and 1:400 for men and women, respectively6. Disease onset is typically seen between 55 and 65, 
but can been seen in patients as young as late teens; frequently, cases seen earlier in life are the 
result of inherited familial ALS (fALS)6. The insidious and rapid progression of ALS lends itself 
to grim prognoses: life expectancy of patients following diagnosis ranges from 2 to 5 years4. This 
expectancy decreases with increased age of onset, early respiratory dysfunction, or initial bALS 
presentation4. Due to the progressive muscle atrophy associated with ALS, weakening 
respiratory muscles eventually lead to resting dyspnea and respiratory failure, frequently 
preceded, and exacerbated, by pneumonia6. 
Despite being the most frequently diagnosed MN disease, only two disease-modifying 
drug exists for the treatment of ALS7. This is largely reflective of the still unclear aetiology and 
pathophysiology of the disease. Riluzole, a glutamate antagonist, was approved for used by the 
FDA in 19948. In two randomized control trials between seven countries in North America and 
Europe, a 100mg daily dose of Riluzole was shown to significantly delay death or tracheostomy 
by 2-3 months, with the greatest delay seen during late-stage ALS8,9. Mortality rates remained 
unchanged. The precise mechanism of action of Riluzole is unknown, but most likely contributes 
to inhibition of glutamate release at the synaptic cleft of MNs, inhibition of voltage dependent 
sodium channels, or inhibition of intracellular events proceeding neuronal10. Glutamate 
excitotoxicity results in excessive influx of calcium-ions to the cell, damaging RNA and DNA, 
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as well as mitochondria. High levels of damage result in spilling of mitochondrial reactive 
oxygen species (ROS) and subsequent cellular death. Edaravone, a small molecule antioxidant, 
was approved for the treatment of ALS by the FDA in 20177. A series of Phase II and III RCTs 
in Japan demonstrated intravenous administration of 60mg edaravone daily, for 10 days per 
month, and over a period of 6 months, can slow the physical decline of early-stage ALS patients 
by 33%11,12. Edaravone is believed to function as a ROS scavenger, minimizing MN and 
neighbouring glial cell death, though officially defined as an unknown mechanism7.  
1.2 TDP-43 and Other Genetic Markers 
Research into the genetics of ALS was largely limited until development of genome 
sequencing. In 1993, SOD1 became the first gene implicated in ALS, shown to harbour 
causative, dominantly inherited mutations13. Since then, over 25 genes and 120 genetic variants 
have been associated with ALS; though the process to determine causality is rigorous14. Due to 
the diverse genetic biology of individuals and aetiology of ALS, causative mutations must be 
validated through reproduction of fALS and sporadic ALS genetic studies, as well as animal 
modelling. Mutations in each of these genes generally affect one or more of the following 
categories: RNA metabolism, protein homeostasis, cytoskeletal dynamics, and glutamate 
excitotoxicity. Despite the genetic diversity of patients, what is common within 97% of ALS 
cases is the propensity of TDP-43 to aggregate into toxic neuronal cytoplasmic inclusions (NCIs) 
and affect the cellular functions listed above15. TDP-43 is an RNA-splicing protein encoded by 
TARDBP. Generally found within the nucleus due to a NLS where it exerts RNA regulatory 
functions, TDP-43 is also capable of nucleocytoplasmic shuttling where it can regulate protein 
synthesis of dendritic component proteins15. ALS-associated mutations in TARDBP are typically 
missense and can cause increased localization to the cytoplasm or overexpression, leading to an 
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abundance within the cytoplasm14. Mutated TARDBP also has a significantly higher chance of 
misfolding14. These mutations occur at a low frequency, albeit causative of ALS16. The high 
incidence rate of TDP-43 proteinopathy and relatively low mutation frequency suggests it plays a 
critical role in disease progression regardless of aetiology. Understanding the mechanism by 
which TDP-43 proteinopathy dampens many essential cellular processes may be crucial to the 
development of new ALS therapeutics which do not target glutamate excitoxicity. Genes with 
mutations known to cause ALS which are discussed in this paper are shown in Table 1. 
Table 1. Several genetic mutations have been shown to be causative of ALS. Functional repercussions of 
these mutations generally influence glutamate excitotoxicity, cytoskeletal dynamics, protein homeostasis, 
and RNA metabolism, demonstrating the various pathogenic pathways of ALS. 
Gene Pathogenic Mechanism Original Study 
PFN1 Cytoskeletal dynamics Wu et al., 201217  
TUB4A Cytoskeletal dynamics Smith et al., 201418 
DCTN1 Cytoskeletal dynamics Munch et al., 200419 
SOD1 Glutamate excitotoxicity, protein 
homeostasis 
Rosen et al., 199320 
TARDBP Cytoskeletal dynamics, protein 
homeostasis, RNA metabolism 
Kabashi et al., 200821 
FUS Protein homeostasis, RNA 
metabolism  
Kwiatkowski et al., 200922 
UBQLN2 Protein homeostasis Deng et al., 201123 
VCP Protein homeostasis Johnson et al., 201024 
OPTN Protein homeostasis Maruyama et al., 201025 
C9orf72 RNA metabolism Renton et al., 201126 
 
1.2.1 Glutamate Excitotoxicity 
 Glutamate is the primary neurotransmitter within mammalian MN system, acting on 
NMDA and AMPA receptors. As previously mentioned (1.1.3 Diagnosis, Epidemiology, and 
Current Therapeutics), the inability to properly clear glutamate from the synaptic cleft or over-
release of glutamate results in hyperexcitation of the postsynaptic neuron, increasing ionized 
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calcium (Ca2+) influx to disrupt mitochondrial function and increase cellular ROS production. 
This excitotoxicity has been implicated in numerous neurodegenerative diseases, not limited to 
ALS27.  
 Excitatory glutamate signalling via AMPA is reliant on proper AMPA receptor 
production, comprised of four heterogenous subunits GluA1-428. The GluA2 subunit is 
responsible for mediating Ca2+ permeability from the extracellular environment, preventing 
hyperexcitation of the post-synaptic neuron28. Post-transcriptional editing of GluA2 mRNA by 
adenosine deaminating acting on RNA2 (ADAR2) is required to maintain an adequate barrier to 
Ca2+ within the AMPA receptor; decreased expression of ADAR2 and Glu2 editing have been 
shown to occur at significantly lower levels in ALS patients, perpetuating AMPA receptor 
activation28. Interestingly, lower expression of ADAR2 also correlated with increased TDP-43 
NCI development28. Clearance of glutamate from the synaptic cleft is mediated in part by 
excitatory amino acid transporter 2 (EAAT2), secreted from nearby astrocytes28. Expression of 
mutant astrocytic SOD1, a dismutase with over 170 known ALS associated genetic variation, 
correlates with up to a 95% decrease of EAAT2 protein levels in sporadic ALS post-mortem 
analyses, however mRNA remained normal, suggesting translational deficits29. While it is 
noteworthy that the only FDA approved pharmaceuticals for the treatment of ALS act in what 
are hypothesized to be mechanisms involving glutamatergic signalling, no other antiglutamateric 
drugs have demonstrated clinically significant effects, suggesting high involvement of other 
pathogenic mechanisms28. 
1.2.2 Cytoskeletal Dynamics and Axonal Trafficking  
Proper maintenance of cytoskeletal dynamics is incredibly important within neurons due 
to the high level of cellular polarization; polar architecture and placement of cellular organelles 
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means that most protein synthesis occurs at local levels, following transportation of required 
substrates from the soma. Inadequate transport leaves more distal locations, such as the synapse, 
unable to properly translate proteins or produce neurotransmitters essential to signal 
transduction. Particularly in MNs where axons may stretch up to 1m before forming the 
presynaptic terminal, transport must remain efficient for neural function and communication 
from motor cortices to muscle cells. Neurofilament (NF) is the primary intermediate filament 
within the axon; disorganization of the NF network has been widely reported in fALS and sALS, 
alike14. NF also participates in cross-bridging to actin filaments and microtubules, forming 
interdisciplinary structural support within the axon30. Actin filaments are polymerized with the 
assistance of actin binding proteins profilin I and II; as such mutations in the encoding PFN1 
gene hinder actin filament production, dampening the structural integrity of the axon and 
capacity for anterograde and retrograde microtubule dependent transport31,32. Appropriately, 
PFN1 mutations are associated with ALS and produce ALS phenotypes in murine models32. 
Microtubule mutations have also been associated with ALS; comprised of alpha and beta-
tubulin, microtubules create a polarized dimer for anterograde and retrograde transport. Genome 
sequencing of fALS patients revealed that TUBA4A mutations, coding for alpha-tubulin, lead to 
decreased polymerization, general cytoskeletal destabilization, and downstream 
neurodegeneration18. Facilitation of substrate transport along microtubule pathways is 
accomplished in part through the dynein/dynactin complex. Mutations in DCTN1, encoding a 
subunit of the dynactin complex, decreases the attachment efficiency of dynactin to 
microtubules, impeding retrograde dynein-mediate transport33. These mutations were shown to 
be causative of ALS in a wide-screen genome sequencing study33. While trafficking of larger 
cargo such as vesicles and organelles is the functional responsibility proteins such as dynein and 
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dynactin, movement of mRNA and other protein synthesis factors along the axon towards the 
presynaptic cleft is facilitated by RNA granules. RNA binding proteins regulate the occupancy 
and movement of these transport granules along the microtubule network. One such RBP is 
TDP-43, who’s interactome includes numerous proteins rooted in synaptic function34. 
Fluorescent imaging studies have demonstrated that cytoplasmic wild-type (WT)-TDP-43 can be 
localized not only within the soma of MNs, but along the length of the axon up to the presynaptic 
cleft35. However, expression of ALS-mutant TDP-43 significantly decreases the level of 
anterograde transport, leading to an accumulation of both mutant TDP-43 and RNA within the 
soma35. Though the mechanism through which mutations in TDP-43 result in decreased 
transport, the possibility can be considered that TDP-43 loss of function (LOF) results in 
perturbations of synaptic protein synthesis and subsequent neurodegeneration.    
1.2.3 Protein Homeostasis 
In non-pathologic states, protein homeostasis is maintained through careful balance of 
protein expression, degradation, and recycling, relying on a variety of pathways: the ubiquitin 
proteasomal system (UPS) for smaller, short-lived, soluble protein; autophagy, for larger, long-
lived proteins, protein aggregates, or organelles; and endoplasmic reticulum refolding. 
Dampening of these pathways results in accumulation of misfolded proteins within the cytosol, 
growing upon themselves to become cytoplasmic inclusions. These cytoplasmic inclusions, 
found within the cytosol of MNs and muscle cells, are a hallmark of ALS.  
Classically thought of as an accumulation of misfolded intermediate filaments such as NF 
resulting from neural degeneration, it is now widely accepted that there exist two populations of 
NCI: that of intermediate filaments, and the novel RNA-binding protein (RBP) NCI. 
Interestingly, the two populations seem to be interconnected – proteins that regulate intermediate 
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filaments and other dendritic and axonal protein expression through mRNA binding are indeed 
the proteins that comprise the RBP NCIs36. Most frequently these proteins include FUS, SOD1, 
and TDP43. TDP-43+ NCIs are notably pervasive and occur in 97% of ALS cases15. The 
sequestering of RBPs typically responsible for the regulation of neural integrity proteins into 
NCIs is suggestive of pathologic depletion of functional cytoplasmic protein preceding 
downstream deficits in neuronal integrity and subsequent neurodegeneration. However, the 
physical presence of NCIs within the cytoplasm has deleterious effects as well. Reflective of the 
maladaptive protein degradation seen in ALS, NCIs promote further cellular distress once 
formed, evoking stress response pathways and secretion of inflammatory molecules creating a 
cytotoxic environment for both MNs and support cells alike.  
Mutant SOD1 is prone to aggregation at significantly higher rates than its WT compart 
and can perpetuate the aggregation of both mutant and WT-SOD1 in a prion-like manner37. 
Similarly, mutated forms of FUS and TDP-43 can also display a prion-like mechanism of 
mutant-propagated aggregation38. This is particularly troublesome in cases where TDP-43 
mutations cause overexpression of the protein. ALS-associated mutations in TDP-43 causing 
overexpression and favourable nucleocytoplasmic shuttling, lead to an abundance of aggregate-
prone protein within the cytoplasm. Overloaded degradative pathways, which would otherwise 
clear excess TDP-43 through autophagy, become futile resulting in the generation of TDP-43-
containing NCIs15. Post-mortem analysis of ALS patient spinal cord and affected cortical areas 
display TDP-43+ NCIs in 97% of cases. These aggregates are also capable of sequestering 
chaperone proteins and ubiquilin, key players in the UPS pathway, adding to aberrant protein 
build up28. It is then not far-reaching to assume that mutations of UPS- or autophagy-involved 
proteins may provoke ALS-like pathology. In fact, mutations of ubilquilin2, vaslon-containing 
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protein, and optineurin – all involved with either proteasome or autophagosome-mediated 
proteolysis – have been linked to ALS28. 
In non-pathologic states, misfolded protein may also be transported to the endoplasmic 
reticulum, unfolded, and refolded into proper conformation with the assistance of endoplasmic 
reticulum chaperone proteins39. This process is termed the unfolded protein response (UPR). In 
diseased states such as ALS where there is an accumulation of misfolded protein, endoplasmic 
reticulum associated degradation (ERAD) and lysosomal degradation is employed to assist with 
the increased burden39. If protein burden remains high, UPR activity becomes analogous to 
constitutively active, increasing the levels of apoptotic signalling molecules from the pathway, 
and terminating in cell death40. Mutant SOD1 has also been shown to bind to integral membrane 
endoplasmic reticulum protein derlin-1, a subunit of Complex 2 of the ERAD control system41. 
The resulting decrease in ERAD efficacy hastens the acuity of UPR-related apoptotic signalling. 
As such, there is fluidity and heterogeneity in the pathways promoting toxic cytosolic protein 
aggregation in ALS.  
1.2.4 RNA Metabolism  
TDP-43 and FUS are important RBPs heavily involved with ALS pathogenesis. 
Previously mentioned to have a strong propensity to misfold and aggregate, producing toxic NCI 
build up for MNs and muscle cells, their consequent LOF has downstream effects on RNA 
processing38. Many of their RNA targets, in fact, code for proteins involved in neuronal 
physiology including dendritic growth and synaptic plasticity; loss of regulation and processing 
of these target RNA therein supresses neural adaptive mechanisms28. Mutations in C9orf72, a 
poorly defined open reading frame (ORF) most likely encoding a not yet recognized guanine 
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exchange factor (GEF), cause additional aberrance of RNA metabolism by generating RNA 
repeats and toxic RNA foci which sequesters both TDP-43 and FUS28. 
Mutated TDP-43 has a strong propensity to aggregate and induce self-propagated 
aggregation of both mutant and WT protein. However, TDP-43 mediated toxicity is not limited 
to its effects on protein homeostasis – as an RNA-binding protein, TDP-43 is responsible for 
regulating the levels of nearly one-third of the transcriptome42. Consequently, mutations do not 
only cause the buildup of TDP-43+ NCIs, but also alter the fate of many RNA products. 
Preferential cytoplasmic localization of mutated TDP-43 undermines the capacity for RNA 
regulatory tasks, to the detriment of neurons. A 2011 study by Moran et al.34 which 
experimentally decreased the levels of TDP-43 expressed within the brains of adult mice 
revealed through massively parallel sequencing that as many as 601 mRNA targets had altered 
levels of expression. Additionally, 965 altered splicing events occurred due to the loss of TDP-43 
splicing activity. The majority of affected targets were products of genes encoding proteins 
involved in synaptic activity, adding to the dysfunctional environment within the neuron34. While 
mutations in TARDBP can directly cause TDP-43 LOF, the consequence of cell-wide TDP-43 
proteinopathy and aggregation is an indirect LOF as well.  
The discovery of ALS-associated mutations in TDP-43 lead to the idea that other RNA 
binding proteins may also play a role in the pathogenesis of ALS, and that aberrant RNA 
metabolism may be a key mechanism in disease progression. Subsequent research unveiled ALS-
associated mutations in FUS. Both are designated as heterogenous nuclear ribonucleoproteins, a 
class of RBPs responsible for diverse, multilevel regulation of RNA metabolism, corroborating 
the theory of disordered RNA metabolism43. The function of FUS largely mirrors TDP-43: an 
RBP mostly constrained to the nucleus due to a NLS with a functional role in RNA metabolism 
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and DNA repair. A small fraction of FUS is localized within the cytoplasm of the axon and 
presynaptic terminal where it regulates translation44. RNA targets of FUS have similar roles to 
that of TDP-43, generally dendritic and synaptic component proteins, however the interactomes 
themselves overlap minimally44. Mutations in FUS associated with ALS are typically dominant 
and result in pathologic loss of RNA regulation essential to neural integrity and downstream 
neurodegeneration, akin to TDP-43 mutations44. 
C9orf72 is also heavily implicated in dysfunctional RNA processing metabolism related 
to ALS. The most common mutations associated with C9orf72 is a G4C2 hexanucleotide repeat 
expansion28. While a genotypical person would normally house 2-23 G4C2 repeats within the 
ORF, patients with C9-associated ALS may carry hundreds to thousands14. The pathogenic 
potential for a repeat expansion typically presents in one of three ways: haploinsufficiency due to 
repeat expansion mutation within the protein, toxic proteinopathy due to accumulation of mutant 
protein within the system, or toxic RNA build up42. Patients with ALS often have lower C9orf72 
expression, consistent with haploinsufficiency, however a 2015 study by Koppers et al.45 
demonstrated that C9orf72 antisense knockout mice did not display deficits in motor function or 
behaviour. Additionally, motor cortices and fontotemporal cortical areas did not display any 
phenotype of ALS pathology, nor did the spinal cord, decreasing the chance that C9orf72 LOF is 
a driver of ALS.  In contrast, adeno-associated viral introduction of G4C2 66-repeat expansion 
C9orf72 induced neurodegeneration, and ALS/FTD behavioural deficits in murine models46. 
Interestingly, introduction of the G4C2 66-repeat also induced TDP-43 proteinopathy, garnering 
further support for TDP-43 as a key pathogenic mechanism of ALS. The transcription of repeat 
RNA can also produce toxic nuclear and cytosolic RNA foci, sequestering RNA binding proteins 
into foci and disrupting RNA processing and metabolism42. The G4C2 repeat in fact can be 
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transcribed bidirectionally, giving rise to both G4C2 and C4G2 repeat RNA; antisense C4G2 foci 
densely pack the nuclear region and increase the propensity of TDP-43 cytosolic mislocalization, 
while G4C2 species are more stable within the cytosol and able to form a G-quadraplex 
secondary structure28, 42. The stable G-quadruplex increases capacity of the foci to travel more 
distally within the cell and accrue local RBPs, possible disrupting local translation47. 
1.3 Physiological Relevance of RGNEF 
1.3.1 Description 
Rho-guanine nucleotide exchange factor (RGNEF) is an approximately 190 kDa protein 
in the Dbl homology family of guanine exchange factor (GEF) proteins48. It is comprised of 5 
major functional domains which regulate its bifunctionalism as both a GEF protein and RBP; the 
amino terminus contains a leucine rich (LeuR) region and a zinc binding domain, the carboxyl 
half contains conserved Dbl and Plekstrin homology domains, and an RNA-binding domain 
(Figure 1)48. First discovered in the cerebral cDNA of a mouse model, RGNEF is now known to 
be expressed in both the human brain and spinal cord, harnessing its functionality as an RBP 
through association with the 3’-untranslated region of low molecular weight-NF (NFL) mRNA 
and acting as a destabilizer49,50. Overexpression of RGNEF is known to decrease levels of 
translated NFL to the detriment of the neuron, compromising structural integrity50. More 
recently, murine and cell-based studies have demonstrated that RGNEF is a stress response 
protein harbouring pro-survival effects51. RGNEF recruitment to RBP NCIs represents a possible 




Figure 1. Map of RGNEF with predicted functional domains. 
1.3.2 Proposed implications RGNEF proteinopathy in ALS 
Similar to RBPs like SOD1, FUS, and TDP-43, RGNEF has been implicated in the 
pathophysiology of ALS, though the mechanism by which it perpetuates disease remains 
unclear49. A small number of fALS cases have been tied to frameshift mutations in RGNEF, 
resulting in a truncated version of the protein with a high propensity to aggregate52. However, 
fALS cases represent a small fraction of ALS case incidence, and RGNEF pathology has not 
been limited to fALS. Indeed, RGNEF has been shown to colocalize with the TDP-43, FUS, or 
Corf72 containing NCIs.  
Immunohistochemical imaging has depicted the presence of both TDP-43 and RGNEF 
colocalizing within spinal motor neuron NCIs of ALS patients, confirming their interaction 
through co-immunoprecipitation36. As such, it is becoming increasingly evident that the 
dysfunctional metabolism of RBPs is an essential factor in ALS disease progression, particularly 
that of TDP-43 and associated RGNEF. Further support for coinciding altered TDP-43 and 
RGNEF metabolism is garnered through an in-vivo study by Droppelmann, et al.53 wherein 
HEK293T cells with lactate-induced metabolic stress displayed significantly increased 
cytoplasmic micronuclei containing both TDP-43 and either full length RGNEF or truncated 
RGNEF with only the LeuR domain. Accordingly, interaction between TDP-43 and RGNEF 
most likely depends on the N-terminal region of RGNEF within the LeuR domain, making it a 
point of interest for the field. Recent findings regarding the LeuR domain of RGNEF continue 
with evidence of cytoprotective characteristics in both murine and cell line models. Following 
distal sciatic nerve injury in a mouse model, expression of RGNEF was markedly increased in 
spinal cord motor neurons, suggesting that RGNEF acts as a stress-response protein51. In the 
same study, HEK293T cells were used to validate stress response of RGNEF in murine models; 
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cells were exposed to oxidative or osmotic stressors, and those transfected with full length 
RGNEF displayed significantly lower percent cytotoxicity. Additionally, cells transfected with 
truncated RGNEF lacking the LeuR domain conferred similar percent cytotoxicity to control 
cells. This increase in cytotoxicity was not seen with recovery of the LeuR domain and 
subsequent deletion of any remaining domains. 
 The RBD of the carboxyl-terminus of RGNEF has also been regarded as a possible 
pathologic locale in ALS. Research has pointed to the aberrant function of RBPs as a key 
mechanism in ALS pathogenesis and progression28. Additionally, regulatory disruption of NF 
mRNA has been implicated in the neurodegeneration of ALS50. Fitting, the RGNEF RBD is 
known to target the mRNA of NFL and regulate its stability50. Mouse models have demonstrated 
that murine homologue p190RhoGEF binds the destabilizing region of NFL to stabilize the 
transcript. This stabilization prevents the aggregation of NFL and subsequent decline in neuronal 
structural integrity resulting from the loss of adequate protein levels. Sequestration of 
p190RhoGEF effectively creates a LOF environment. In contrast, realization of the human 
homologue demonstrated its function as a destabilizing factor for human NFL; overexpression of 
RGNEF within HEK293T cell lines causes a significant decrease in levels of NFL mRNA as 
measured using a luciferase probe50. Levels of NFL mRNA were recovered when using an 
RGNEF construct lacking the RBD. The contrasting findings of these studies demonstrated the 
need to further investigate the mechanism of RGNEF NFL regulation in pathologic and non-
pathologic states, particularly as ALS is not a naturally occurring disease in mice.  
1.4 Rationale and Significance 
Previous research has demonstrated that RNA metabolism and the function of RBPs, 
notably that of TDP-43 and RGNEF, is maladaptively altered in ALS and plays crucial role in 
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disease progression28,53. Notably, TDP-43 has been demonstrated to be involved with a wide 
range of pathogenic mechanisms and is highly colocalized with RGNEF – a protein which 
typically confers cytoprotection and regulates levels of NFL53. It is then conceivable that the N-
terminal associated cytoprotection of RGNEF may offer a therapeutic benefit to the down-stream 
degenerative effects of TDP-43 positive NCIs. In turn, this may have far reaching implications 
for a large population of ALS patients considering the prevalence of TDP-43 positive NCIs if it 
is assumed RGNEF colocalizes with TDP-43 at the rate of TDP-43+ NCI occurrence, 
approximately 97% of ALS cases. For this reason, determining the nature of the interaction 
between RGNEF and TDP-43, as well as the physical structure of RGNEF, is paramount to 
understand the recruitment and interaction between TDP-43 and RGNEF. The mechanism by 
which RGNEF interacts and regulates NFL and other mRNA targets remains unclear, and 
elucidation may hold further information surrounding the nature of structural degeneration in 
ALS-affected MNs.  
1.5 Experimental Approach and Aims 
 To further our understanding of the biophysical characteristics of RGNEF and the 
interactome of the both N-terminal and C-terminal regions, truncated constructs of RGNEF will 
be designed and expressed using E. coli competent cells. Expressed protein will be purified for 
the purpose of analyzing biophysical properties using methods including thermal shift assay and 
size exclusion chromatography-multiangle light scattering (SEC-MALS). Interaction between 
RGNEF and TDP-43 will be tested via surface plasmon resonance (SPR) using purified RGNEF 
constructs which will provide the first definitive evidence of whether a direct interaction between 
the proteins exists.  
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Chapter 2 - Methodology 
2.1 Construct Design and Expression 
2.1.1 Determination of construct perimeters and polymerase chain reaction (PCR) 
Constructs were designed based on the sequence of a pUC-57 full-length RGNEF 
plasmid codon-optimized for E. coli expression (hereon referred to as FL-RGNEF), synthesized 
by BioBasic (Ontario, Canada). 
Using Phyre2, a predictive secondary structure and homology modelling program, the 
amino acid sequence of FL-RGNEF was input to determine regions of high confidence order or 
disorder and predicted domain locations54. Regions with high confidence disorder were excluded 
from constructs; regions with high confidence order were included. Regions of high confidence 
order were concentrated around the 5 predicted functional domains of RGNEF and decreased 
variably as distance from functional domains increased. As such, multiple constructs were 
designed for each domain with a variety of termination locations. A total of 33 constructs were 
designed; five went on to be used for this study (Figure 2A).  
Constructs were produced via polymerase chain reaction using PrimeSTAR GLX DNA 
polymerase (Takara Bio, California, USA). Forward and reverse PCR primers were designed for 
each terminating sequence with an approximate initial melting temperature of 60qC. FL-RGNEF 
was used as template DNA for each reaction. PCR reactions were completed using the 
Eppendorf MasterCycler Pro (Ontario, Canada) staring at 98C for 5 min, proceeded by the 
















Figure 2 A-C. RGNEF constructs were designed based on secondary structure predictions from Phyre254. 
Structure prediction and disorder confidence vary along the Phyre2 colorimetric key of High (red) to Low 
(indigo). Output for the predicted LeuR region is displayed in panel (B), output for predicted RBD is 
C 
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displayed in planel (C). Detailed in panel (A) are the boundaries of each truncation, with ranges indicated 
in amino acids.  
* Designates constructs used for the purpose of this study. The remainder were created and stored in the 
Junop Lab Plasmid Library for future use.  
 
2.1.2 Cloning and vectors 
Using the Gateway Cloning (Thermo Scientific, United States) method as per 
manufacture’s protocol, the PCR products for each construct were cloned into kanamycin-
resistant pDONR201 entry vector via BP reaction. Plasmids DNA was then combined with 50PL 
of BL21DE3T1R E. coli competent cells, heat shocked for 50s in a water bath at 42qC and 
cooled on ice for 2min. Cells were allowed to recover for 45min in a 37qC shaking incubator at 
225rpm, with the addition of 50PL standard Lennox-Broth (LB) media. Cells were plated onto 
kanamycin-LB-agar plates and left to grow overnight at 37qC. Single colonies were then selected 
and grown in 10mL of kanamycin-inoculated LB media for 16-18h in a 37qC shaking incubator 
at 225rpm.  Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen, Ontario, 
Canada) as per manufacturer’s protocol. A sample from each construct underwent restriction 
enzyme digestion and subsequent agarose gel electrophoresis to validate sequence identity. 
Sequence identity was then more carefully verified through DNA sequencing at the DNA 
Sequencing Centre, Robarts Research, University of Western Ontario.  
Entry of pDONR201 plasmid DNA into expression vectors was facilitated via LR 
reaction, the second step of Gateway Cloning (Thermo Scientific, United States), completed as 
per manufacture’s protocol. The DNA of each construct was placed into 2 expression vectors: 
pDEST527 and pDEST566. pDEST527 contained a T7 promoter for desired gene expression and 
N-terminal 6xHIS-tag attached to the entry gene by a short linker sequence for affinity 
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chromatography. In light of literature suggesting the pervasive insolubility of RGNEF, 
pDEST566 was selected as the second expression vector as it contained an N-terminal MBP-
6xHis fusion-tag for improved protein solubility during affinity chromatography purification. 
Protein expression in the pDEST566 vector was as well under the control of a T7-promoter. LR 
reaction products were mixed with 50PL of BL21DE3T1R competent cells, heat shocked for 50s 
in a water bath at 42qC and cooled on ice for 2min. Cells were immediately plated on ampicillin-
LB-agar plated and incubated at 37qC overnight. The next morning, single colonies were then 
selected and grown in 10mL of ampicillin-inoculated LB media for 16-18h in a 37qC shaking 
incubator at 225rpm. Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen, 
Ontario, Canada) as per manufacturer’s protocol and stored at -20C as expression plasmid stock. 
Table 2 A-C display all RGNEF vectors produced by this method and used in this study.  
Table 2 A-C. Donor (Table 2 A) and expression (Table 2 B, C) plasmids of RGNEF made using Gateway 
Cloning, including forward (F) and reverse (R) primers which were used in conjunction with FL-RGNEF 
during PCR to create each construct. X Denotes constructs which were unable to be produced to 
completion during cloning due to mutation errors. * Denotes constructs which were used for the purpose 
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2.2 Validation of Autoinduction Method 
While not all possible constructs were used for the purpose of this study, all were to be 
screened in small scale solubility testing and added into the Junop Lab Plasmid Library. As 
nearly each truncation was cloned into both pDEST527 and pDEST566 expression vectors, there 
were just fewer than 60 constructs to screen (some of the initial 66 had been discarded due to 
persistent mutations during the PCR and cloning process). For this reason, a higher throughput 
method with less consistent monitoring than traditional isopropyl β- d-1-thiogalactopyranoside 
(IPTG) induction in LB was ideal. Using Studier’s autoinduction media (Table 3), E. coli were 
able to self-induce plasmid expression through a progressive increase in lactose metabolization, 
eliminating the need to monitor OD and allowing multiple constructs to undergo solubility 
screening simultaneously55. The efficacy of induced expression using autoinduction media was 
validated using a control plasmid with a known expression profile from the Junop Lab. The 
control plasmid was heat shocked into 50PL BL21DE3T1R competent cells for 50s in a 42qC 
water bath then placed on ice for 2mins. Cells were plated on ampicillin-LB-agar plates and left 
to grow overnight at 37qC. The next morning a colony was selected and grown in 10mL 
ampicillin-inoculated LB media for 16-18h at 37qC in a shaking incubator at 225rpm. 100PL of 
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the culture was then diluted into 10mL of ampicillin-inoculated autoinduction media to create 
secondary cultures. Multiple autoinduction cultures were made to study expression profiles from 
various temperatures, and with various durations of growth. One secondary culture was also 
grown using 10mL LB media with standard IPTG induction once optical density reached 0.6 to 
obtain the control expression profile. This culture was grown at 37qC in a shaking incubator at 
225rpm. Protein extraction was then completed using B-PER (Thermo Scientific, United States), 
a chemical lysate, as per manufacture’s protocol. 15% sodium dodecyl-sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) was performed on soluble and insoluble protein fractions to 
determine the time and temperature of autoinduction growth which optimized protein expression. 
The same process was repeated for an RGNEF construct to validate time and temperature using 
autoinduction in comparison with its LB-IPTG compart.  
Table 3. Studier’s Autoinduction Media used for growth of RGNEF constructs. Following autoclave 
sterilization of the base broth and cooling overnight, filter sterilized sugars and glycerol could be added to 





2.3 Protein Expression and Purification 
2.3.1 Small Scale Solubility Testing 
 To determine the plausibility of successful RGNEF construct purification in the large-
scale, constructs underwent small scale solubility testing. 50ng of expression plasmid stock DNA 
was mixed with 50PL of BL21DE3T1R E. coli competent cells, heat shocked for 50s in a 42qC 
water bath and left on ice for 2mins. Cells were then plated onto ampicillin-LB-agar plated and 
incubated overnight at 37qC. Single colonies were then selected and grown in 10mL LB media 
inoculated with ampicillin for 16-18h in a 37qC shaking incubator at 225rpm. 100PL of this 
primary culture was then diluted into 10mL of autoinduction media inoculated with ampicillin 
and grown for 4h at 37qC in a shaking incubator at 225pm, followed by 20h at 16qC. Protein was 
extracted using B-PER (Thermo Scientific, United States) as per manufacture’s protocol, 
providing a soluble and insoluble protein fraction. Samples from each fraction were run on 15% 
polyacrylamide gel SDS-PAGE for 1h at 165V to determine degree of soluble protein recovery.  
2.3.2 Large Scale Expression 
 Constructs selected to move to large-scale growth and purification were transformed and 
grown in 10mL LB media cultures following an identical protocol to 2.3.1 Small Scale Solubility 
Testing. The entirety of the primary culture was then diluted into 1L autoinduction media in a 
wide-bottom 4L Erlenmeyer flask, inoculated with ampicillin. 1L cultures were grown for 4h at 
37qC, followed by 20h at 16qC in a shaking incubator at 220rpm. The contents of 1L cultures 
were then centrifuged for 15min at 4000rpm to harvest E. coli cells. Supernatant media was 
discarded, and cells were resuspended and washed in approximately 15mL 1x phosphate-
buffered saline (PBS). Cell suspensions were centrifuged for 20min at 3500rpm to recover a final 
cell pellet which was immediately placed into storage at -80qC for later purification.  
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2.3.3 Protein Purification 
 Cell pellets were thawed from -80qC storage at room temperature. The weight of thawed 
pellets was measured, and pellet were resuspended in approximately 10mL/g cell pellet of filter 
sterilized nickel-A running buffer (Ni-A) comprised of 800mM NaCl, 20mM Tris-HCl pH 8.0, 
and 10% v/v glycerol. A mixture of 100x water soluble and ethanol soluble protease inhibitors 
were added for a working concentration of 1x. Cell suspensions were then lysed by French 
Pressure Cell, and protease inhibitors added to cell lysate. Cell lysates were centrifuged for 
50min at 20 000rpm to separate soluble protein from insoluble protein. Fractions were separated, 
insoluble protein pellets were stored at -20qC for later sampling, and soluble protein was 
harvested and treated with a final volume of water-soluble protease inhibitors only.  
 Purification of RGNEF protein was completed by nickel-immobilized metal affinity 
chromatography (Ni-IMAC) on an ÄKTA Start Protein Purification System (Cytiva Life 
Sciences, United States) equipped with a 5mL HiTrap HP column (Cytiva Life Sciences, United 
States). Soluble protein was injected onto the column at a rate of 0.5mL/min, followed by an 
approximately 50mL wash of Ni-A at 2mL/min. Non-specific proteins were then washed from 
the column at 2.0 mL/min with either an isocratic or gradient increase of filter-sterilized nickel-B 
elution buffer (Ni-B) containing 800mM NaCl, 300mM imidazole, 20mM Tris-HCl pH 8.0, and 
10% v/v glycerol. The selection of isocratic or gradient increase of Ni-B was dependent on 
whether it was the first attempt of construct purification (typically isocratic for increased control 
and monitoring) or subsequent purifications (typically gradient, requiring minimal monitoring). 
Washing of the non-specific proteins would continue until a 15% v/v Ni-B/Ni-A was reached. A 
static wash of approximately 50mL 15% Ni-B at 2.0mL/min was then completed. Elution was 
completed at a rate of 1.0mL/min in 100%v/v Ni-B. As RGNEF constructs were designed with 
 33 
an N-terminal 6xHis-tag in both pDEST527 and pDEST566, their affinity to the column was 
such that they are only out-competed by concentrations of imidazole 210mM or higher, 
corresponding to 70%v/v Ni-B/Ni-A. For this reason, 100% Ni-B elution fractions were 
presumed to contain RGNEF construct protein and were immediately sampled for SDS-PAGE 
and stored at -80qC. Other fraction collected throughout the purification were sampled for SDS-
PAGE and stored at -20qC. SDS-PAGE samples were combined with 2xSDS dye with 5% BME 
for a working concentration of 1x, boiled for 6min, and centrifuged at 14 000 x g for 8 min. A 
15% w/v polyacrylamide gel SDS-PAGE was then run at 165V for 1h to confirm the location of 
RGNEF construct protein. Chromatography data analysis during purification was done using the 
UNICORN 7 software (Cytiva Life Sciences, United States).  
2.3.4 Western Blot 
 Western blotting was performed on a select number of SDS-PAGE gels, run as described 
above. Following completion of the 1h 165V electrophoresis, the Western Blot cassette 
assembled in transfer buffer (25mM Tris, 190mM glycine, 20% v/v glycerol) and run for 65min 
at a constant current of 225A to transfer protein onto the membrane. The transferred membrane 
was then soaked in blocking buffer (Tris-buffered saline with 0.1% Tween 20 detergent (Sigma 
Aldrich, Canada) (TBST) and 5% bovine serum albumin (BSA)) for 1h at room temperature. The 
membrane was then soaked in TBST supplemented with primary Anti-6xHis-tag mouse 
monoclonal antibody (Product # 37-2900, Invitrogen, Ontario, Canada) overnight at 4qC. The 
next morning the membrane was washed three times with TBST + 3% BSA, each for 10min at 
room temperature. The membrane was then incubated with TBST + 3% BSA supplemented with 
goat anti-mouse IgG secondary antibody, conjugated with alkaline phosphatase (AP) (Product # 
A16069, Invitrogen, Ontario, Canada). Detection of the 6xHis-tag was done visually through the 
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chemiluminescence of AP following use of AP Conjugate Substrate Kit (BioRad, Ontario, 
Canada) and documented via photograph.  
2.3.5 Size Exclusion Chromatography 
 Size exclusion chromatography (SEC) was performed on the ÄKTA Start Protein 
Purification System (Cytiva Life Sciences, United States) using HiPrep 16/60 Sephacryl S-
300HR (Cytiva Life Sciences, United States). Protein purified by Ni-IMAC was injected onto the 
column at 1.0mL/min, which remained for the duration of the experiment. Fractions were 
collected in 1mL volumes for easy isolation of elutants over the entirety of the experiment. 
2.4 Biochemical Analysis 
2.4.1 Thermal Shift Assay 
 As the physical characteristics of RGNEF remain uncharacterized in the literature, and 
there has been significant difficulty over the years with purification of RGNEF, pH and salt 
screening thermal shift assays were performed on purified constructs to determine optimal buffer 
conditions for future experiments. The Durham pH Screen (Molecular Dimensions, England) and 
The Durham Salt Screen (Molecular Dimensions, England) were used to analyze purified 
constructs in a variety of conditions. Each screen contained 96 different solutions which could be 
combined with protein to analyze their stability in various conditions. Purified protein had to be 
within 1.0-1.5mg/mL for optimal plate reading. Protein was thawed on ice and 1PL/mL-protein 
of SYPRO Orange Protein Stain (Thermo Scientific, United States) was added. In a 0.1mL-96-
well plate, 10PL of protein was combined with 10PL of screen condition. The plate was covered 
with a clear, optical seal and placed in the QuantStudio5 Real-Time PCR (Applied Biosystems, 
Ontario, Canada) where method temperature began at 12qC and increased at a steady rate of 
0.2qC/s until 60qC was reached. Fluorescence reading from stained protein was used as a 
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measure of total stable protein. As protein denatured under the various conditions at increasing 
temperatures, fluorescence would increase accordingly. Thermal shift data analysis was 
completed using Protein Thermal Shift Software v1.4 (Applied Biosystems, Ontario, Canada). 
2.4.2 Size Exclusion Chromatography-Multiangle Light Scattering  
 Size exclusion chromatography-multiangle light scattering (SEC-MALS) was graciously 
completed with the assistance of Megan Noble of the Stathopulos Lab (Schulich School of 
Medicine and Dentistry, Western University, Canada). Purified pMJ5899 was dialyzed overnight 
at 4qC into a 50mM sodium citrate tribasic-HCl pH 5.5, 300mM NaCl, 0.5mM DTT running 
buffer. SEC was performed using a GE Healthcare Superdex 200 10/300 GL Increase column 
(GE Healthcare, United States) and MALS performed using a HELEOS II detector system 
(Wyatt Technology Corporation, United States). Equilibration of the SEC-MALS system with 
running buffer ran at 0.5mL/min for at least 1 column volume or until MALS detection baseline 
was less than 0.02mV, which ever took longer. Following equilibration, 100PL of purified 
pMJ5899 was injected into a 100PL sample loop which began the SEC-MALS experimental 
method. The experimental method occurred at a flowrate of 0.5mL/min. Light scattering data 
was collected by HELEOS II and analyzed using the ASTRA software to calculate the MW of 
purified pMJ5899 (Wyatt Technology Corporation, United States). Eluted SEC samples were 
collected in a 96-deep-well plate and analyzed using SDS-PAGE.  
2.4.3 Surface Plasmon Resonance 
 Surface plasmon resonance (SPR) was graciously completed by Dr. Crystal McLellan of 
the Strong Lab (Robarts Research Institute, Western University, Canada) using the Reichert 
2SPR, SR7500DC System (Reichert, New York, USA). Purified pMJ5899 was dialyzed into 
1xPBS, diluted to 100Pg/mL with 10mM NaAc-HCl pH 4.0, and immobilized onto a 
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carboxymethyl dextran SPR chip via 6xHis-tag. A TDP-43 construct kindly donated by Dr. 
Stanley Dunn (Shulich School of Medicine and Dentistry, Western University, Canada) was used 
as experimental analyte. The TDP-43 construct ranged TDP-431-103 and was altered cysteine-free 
as it was previously used for crystallographic analysis (hereon referred to as TDP-431-103CF). 
Reference channel on the same chip, which did not contain immobilized purified pMJ5899, was 
run in tandem with the experimental channel to produce a baseline that would allow for 
quantification of purified pMJ5899/TDP-43 interaction. A running buffer of 1xNBS-PBST 
(0.2% Tween, 1% BSA, 400 nM NaCl) was used throughout the experiment. Once purified 
pMJ5899 was immobilized, a 1M ethanolamine wash followed by regeneration solution (1M 
NaCl, 10% v/v glycerol) wash was performed to prepare the chip for the experimental method. 
Reverse serial dilutions of TDP-431-103CF into 10 mM NaAc-HCl pH 4.0 were used as analyte 
(1.25PM, 2.5PM, 10PM), each followed by a regeneration solution wash, 1xPBST blank wash, 
and 10 mM NaAc-HCl pH 4.0 buffer wash. Degree of purified pMJ5899/ TDP-431-103CF 
interaction was measured in micro-Response Units (PRIU) and data analyzed using SPR 
Autolink 1.1.14-T (Reichert, United States).  
2.4.4 Electrophoretic Mobility Shift Assay  
 Electrophoretic mobility shift assay (EMSA) was performed using purified RGNEF 
protein and a 25-mer poly-U RNA probe with a 5’-6-FAM fluorescent tag (Integrated DNA 
Technologies, United States). In the set of 20PL reactions, the concentration of purified RGNEF 
was decreased step-wise by dilution with buffer to maintain salt and pH. 1PL of 1.0PM RNA 
probe and 2PL 10xBSA were then added. Reactions were incubated on ice for 15mins and 
combined with 4PL 6xDNA dye with glycerol to help samples settle to the bottom of gel wells 
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during electrophoresis. Samples were then run on a 10w/v% native-PAGE gel for 70min at 100V 




Chapter 3 - Results 
3.1 Autoinduction Media Induces Protein Expression 
 Thirty-three construct boundaries were designed from the FL-RGNEF sequence. Each 
construct was cloned into both pDEST527 and pDEST566 expression vectors; controlling for 
constructs lost due to mutations during the cloning process, the total number of constructs was 73 
(a total of 99 were designed, 26 were eliminated to mutation). While not all constructs were used 
for the purpose of this study, all were produced in tandem and available for further studies if 
needed. Subsequently, each construct underwent small-scale protein purification in tandem to 
predict solubility prior to being used in a large-scale purification. Most commonly, expression of 
target protein under the control of a T7lac promoter using E. coli competent cells is done by 
closely monitoring the optical density of E. coli cultures in LB media and subsequent induction 
of expression with the addition of IPTG. With around 60 constructs to test, a high throughput 
growth protocol requiring minimal monitoring was preferable to allow for culture growth and 
induced expression of multiple constructs concurrently. Studier’s Autoinduction Media was 
designed for this purpose55. The recipe, which includes lower glucose and higher lactose levels 
relative to LB media, promotes steady glucose-dependent growth followed by log phase lactose-
dependent growth, producing metabolites which induce target protein expression. Levels of 
protein expression in autoinduction cultures are consistently higher than LB-IPTG cultures, 
which may run the risk of overexpression and subsequent aggregation of our target protein. This 
prompted a validation step to determine the proper time course of autoinduction culture growth 
to obtain a similar expression level to LB-IPTG culture. To do so, a control protein from the 
Junop Lab with a known LB-IPTG expression profile was grown in autoinduction media with 
samples collected at various timepoints to be compared using SDS-PAGE. The duration of 
 39 
autoinduction growth best resembling the expression profile from LB-IPTG growth was then 
implemented with an RGNEF construct, pMJ5897, selected as it is the largest construct from the 
N-terminal region of the protein, and tested to validate expression levels in RGNEF.  
 SDS-PAGE of samples taken from both the IPTG-induced control protein as well as an 
array of autoinduction culture growth times showed that autoinduction cultures highly induced 
soluble target protein expression after sustained growth at low temperature preceded by acute 
duration growth at a higher temperature. The acute duration growth at a high temperature likely 
did not result in protein expression alone as E. coli were still able to utilize the small glucose 
concentration within the media. However, as the doubling time for E. coli culture growth at 37C 
is approximately 25 minutes, high temperature growth allowed for the creation of a highly 
populous culture which was then able to induce high levels of expression during low temperature 
growth. Visual quantification of SDS-PAGE bands suggested that similar levels of control 
protein were seen following 4h at 37qC + 20h at 16qC. 
 This assay was then completed on pMJ5897 without alterations to durations of growth. 
SDS-PAGE results were extremely similar to that of the control protein, showing highly induced 
expression following 4h at 37qC, followed by sustained low temperature growth. The level of 
protein expression following 4h at 37qC + 20h at 16qC was slightly higher than that of the IPTG-
induced culture, however as we were unsure whether protein solubility would be maintained 
during a large-scale growth given the difficult nature of RGNEF, it was decided to maintain the 
4h at 37qC + 20h at 16qC timeline.  
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Figure 3A-B. Validation of Autoinduction protocol between a control protein (A) and pMJ5897 (B). 
IPTG-induced cultures were grown in LB until OD = 0.6, while autoinduction cultures were grown and 




States), soluble and insoluble fractions were collected. It was decided that 4h at 37qC + 20h at 16qC gave 
optimal autoinduced-expression. 
 
3.2 Purification of N-terminal Constructs 
3.2.1 Purification of pMJ5897 
 Construct pMJ5897 covers the largest region of the N-terminal domain of RGNEF 
(amino acids 1-395), including the entirety of the predicted interacting region between RGNEF 
and TDP-43. For this reason, it was selected to be the first construct for purification. pMJ5897, 
being expressed in the pDEST566 vector, included a 40.2kDa 6xHis-MBP-fusion tag linked to 
the 44.0kDa construct for an open reading frame (ORF) molecular weight of 87.9kDa. Following 
culture growth of pMJ5897, 7g of cell pellet were harvested, resuspended in Ni-A buffer and 
lysed by French Press. Soluble and insoluble lysate fractions were separated by centrifugation, 
leaving approximately 60mL of soluble lysate. Soluble lysate was pumped onto a 5mL HiTrap 
HP column (Cytiva Life Sciences, United States) Ni-IMAC column at 0.5mL/min at room 
temperature. Inclusion of a 6xHis-MBP tag promoted strong association of the target protein 
with Ni2+ charged resin beads within the column. This permitted a gradient wash of the column 
from 0-15% Ni-B (0-45mM imidazole) for the removal of impurities, followed by a static 15% 
Ni-B wash. Elution of pMJ5897 was performed at 100% Ni-B (300mM imidazole) which 
reached a peak UV absorption of 2000mAu (the maximum reading on the AKTA Start 
Purification system), plateauing for approximately 5mL before steadily decreasing over 20mL. 
9.2mL of elution protein was collected during the UV peak with a concentration of 7.51mg/mL 
as measured via Nanodrop. SDS-PAGE of samples taken throughout the purification process 
gave visual confirmation of a strongly induced, soluble protein species running at approximately 
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85kDa with an elution positively correlating with imidazole concentration; this was presumed to 
be pMJ5897 (Figure 4).  
 
Figure 4. SDS-PAGE of Ni-IMAC purification samples of pMJ5897. pMJ5897 was highly induced and 
appeared at high levels during 100% Ni-B elution. The green arrow indicates location of pMJ5897.  
 
 Addition of the 6xHis-MBP fusion tag seemed to be effectively solubilized pMJ5897 
during purification. This is particularly notable as the N-terminal region of RGNEF has yet to 
have a described purification in the literature and is cited as being “difficult to clone, express and 
purify”56. However, the preference moving forward for biophysical analysis of pMJ5897 was 
removal of the fusion tag to circumvent difficulties in protein characterization which could occur 
due to the large size of the fusion tag itself or flexibility of the linker region between the fusion 
tag and the RGNEF construct. For this reason, 200PL of 7.51mg/mL elution protein was sampled 
to undergo TEV enzymatic cleavage to remove the fusion tag from the RGNEF construct. 
Protein was dialyzed overnight into 500mL of TEV Protease reaction buffer (200mM KCl, 
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50mM Tris HCl pH 8.0, 0.5mM EDTA, 1mM BME). Protein concentration of the 200PL sample 
remained the same following dialysis, leaving 1.5mg of protein available for the reaction. A 
standard reaction ratio of 15:1 protein:TEV protease was followed, with the addition of 100PL 
TEV protease (1mg/mL). The reaction was left in an Eppendorf tube for 24h at 4qC. 
Subsequently, there presented no evidence of protein precipitation before or after quick 
centrifugation of the reaction tube. SDS-PAGE analysis demonstrated approximately 50% 
cleavage efficacy (Figure 5). Despite lower than ideal efficacy, it was decided to move forward 
with a large scale TEV protease reaction due to relatively high pMJ5897 elution concentration 
and volume (9.0mL at 7.51mg/mL). 5mL of pMJ5897 elution protein was buffer exchanged into 
200mM KCl, 50mM Tris HCl pH 8.0, and 0.5mM EDTA using a HiPrep 26/10 Desalting 
column (Cytiva Life Sciences, United States), with the recovery of 9mL at 2.00mg/mL (18mg) 
collected into a 50mL falcon tube. BME was added following buffer exchange for a final 
concentration of 1mM. Attempting to increase cleavage efficacy, the reaction ratio was increased 
to slightly over 10:1 with the addition of 2x1mL aliquots of 1mg/mL TEV protease, and the 
reaction time increased from 24h to 48h. SDS-PAGE using sampled from the large-scale reaction 
displayed a similar cleavage efficacy to the small-scale test, suggesting that the remaining 
uncleaved protein was inaccessible to TEV protease (Figure 5). Reverse Ni-IMAC was used to 
isolate cleaved, untagged RGNEF protein from both uncleaved protein and cleaved 6xHis-MBP. 
The 10mL reaction solution was buffer exchanged into Ni-A buffer and loaded onto a 5mL 
HiTrap HP column (Cytiva Life Sciences, United States) a 0.5mL/min. Cleaved protein was 
expected to flow through the column during the initial 100% Ni-A wash, however there was 
minimal UV absorption to indicate this, peaking at 24mAu. A stepwise increase in Ni-B buffer 
from 0-20% likewise displayed minimal UV absorption. Elution of remaining bound proteins at 
 44 
100% Ni-B, which would predictably include uncleaved pMJ5897 and cleaved 6xHis-MBP, 
showed a sharp peak at 2000mAu which quickly receded. SDS-PAGE of samples taken through 
the reverse Ni-IMAC process displayed minimal visible protein, apart from elution samples 
which showed faint banding around 85kDa and 40kDa, the expected molecular weights (MWs) 
of uncleaved pMJ5897 and 6xHis-MBP, respectively. To explain the disappearance of protein, 
cleaved RGNEF protein and 6xHis-MBP along with uncleaved pMJ5897 may have formed 
soluble aggregates due to the hydrophilicity of MBP. These soluble aggregates may have 
occupied the column throughout the 100% Ni-B elution, outcompeting imidazole. Unfortunately, 
this theory was not considered before the used column was stripped and recharged. Size-
exclusion chromatography was suggested to resolve cleaved RGNEF from other products in the 
TEV reaction, however this idea was dismissed due to the relatively similar size of the 6xHis-
MBP tag (40.2kDa) and the RGNEF construct (44.0kDa). It was then decided to move forward 
with the purification of a construct with a larger size differential between the protein and fusion 
tag.  
  A 
B C 
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Figure 5 A-C. (A) SDS-PAGE testing the efficacy of TEV cleavage on pMJ5897 in a small-scale test at a 
15:1 ratio. TEV appears in the first lane just above 25kDa and can be seen in the subsequent lanes. 6xHis-
MBP (40.2kDa) appears in the second lane between 35-50kDa, but is superimposed by RGNEF1-395 
(44.0kDa). Uncleaved pMJ5897 is seen in the third lane. (B) SDS-PAGE of large scale TEV cleavage 
samples. (C) Attempted isolation of RGNEF1-395 using reverse Ni-IMAC following TEV reaction of 
pMJ5897. Minimal to no recovery of RGNEF1-395 can be seen in the flow-through. 
   
3.2.2 Purification of pMJ5913 
 Following the difficulties isolating the cleaved RGNEF protein of construct pMJ5897 
from both uncleaved pMJ5897 and cleaved 6xHis-MBP, it was decided to attempt the 
purification of a construct which could be better resolved based on a larger size differential from 
the 6xHis-MBP tag. Construct pMJ5913 was decided as an optimal construct as it contained the 
smallest predicted LeuR organized region of the N-terminus, RGNEF94-219 (Figure 6), with a 
molecular weight of 17.2 kDa (excluding the 6xHis-MBP and remainder of the ORF, total ORF 
molecular weight = 57.45 kDa). Following culture growth, 7g of cell pellet were harvest and 
resuspended in 70mL of Ni-A buffer, lysed via French Press cell, and centrifuged to isolate 
soluble and insoluble lysates. 60mL of soluble lysate was recovered and pumped onto a 5mL 
HiTrap HP column (Cytiva Life Sciences, United States). Ni-IMAC column at 0.5mL/min at 
room temperature. Similar to the purification of pMJ5897, a gradient wash of the column from 0-
15% Ni-B (0-45mM imidazole) was used for the removal of impurities, followed by a static 15% 
Ni-B wash. Elution of pMJ5913 was performed at 100% Ni-B (300mM imidazole) which 
reached a peak UV absorption of 2000mAu (the maximum reading), plateauing for 
approximately 2mL before steadily decreasing over 16mL. 15mL of elution protein at 
3.574mg/mL was recovered from fractionation during the peak UV reading, totalling 53.61mg of 
pMJ5913 protein. SDS-PAGE analysis of samples taken throughout the purification process 
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confirmed a highly induced, soluble protein which eluted at high levels during administration of 
100% Ni-B buffer and ran at approximately 55kDa, visually confirming the induction and 
purification of 57.45 kDa pMJ5913 (Figure 6). 
 
Figure 6. SDS-PAGE of Ni-IMAC purification samples of pMJ5913. pMJ5913 was highly induced and 
appeared at high levels during 100% Ni-B elution. The green arrow indicates location of pMJ5913. 
 
 For later biophysical analyses of pMJ5913, removal of the 6xHis-MBP tag was preferred. 
Following difficulties cleaving the fusion tag from pMJ5897, it was decided to assay varying 
reaction ratios over 48h and 72h. Two 250PL samples of elution protein were dialyzed overnight 
into 500mL each of 200mM KCl, 50mM Tris HCl pH 8.0, 0.5mM EDTA, 1mM BME at 4C. 
Protein concentration following dialysis was 3.273 mg/mL. Two sets of four 50PL protein:TEV 
conditions were created (15:1, 10:1, 8:1, 4:1, 2:1) with one set left at 4qC for 48h and one for 
72h. No conditions presented any evidence of protein precipitate. SDS-PAGE analysis of 
samples taken from both 48h and 72h reactions show no visible difference between the durations 
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of reaction (Figure 7) and minimal visible difference with increasing TEV protease concentration 
beyond an 8:1 ratio (Figure 7).  
 
Figure 7 A-B. (A) 48h TEV cleavage assay of pMJ5913.  Increased TEV concentration did not 
significantly increase the degree of pMJ5913 cleaved. (B) 72h TEV cleavage assay of pMJ5913. Similar 
results were seen to that of the 48h assay, indicating that increased time did not increase cleavage 
efficacy.  
 
Similar to pMJ5897, this indicated that there remained a subpopulation of pMJ5913 that 
was inaccessible to TEV protease. However, due to the larger size differential between the 
6xHis-MBP and the inserted RGNEF truncation, it was possible that cleaved protein could be 
isolated using SEC. It was decided to complete a large-scale TEV digest at an 8:1 ratio over 48h 
at 4qC. 10mL of elution protein was buffer exchanged into 200mM KCl, 50mM Tris HCl pH 8.0, 
and 0.5mM EDTA using a HiPrep 26/10 Desalting column (Cytiva Life Sciences, United States), 
with the recovery of 15mL at 2.487mg/mL (37.31mg) collected into a 50mL falcon tube. BME 
was added following buffer exchange for a final concentration of 1mM. TEV protease was added 
A B 
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for a final ratio of 8:1 protein:TEV and left for 48h at 4C, after which there was no evidence of 
precipitation. The reaction solution was injected and processed on a HiPrep 16/60 Sephacryl S-
300HR (Cytiva Life Sciences, United States). Unicorn software analysis displayed four distinct 
peaks, with the first peak showing bidispersity and the final peak occurring after one full column 
volume, typical of a salt peak. SDS-PAGE analysis of samples taken from the first bidisperse 
peak show uncleaved pMJ5913 (57.45 kDa) and cleaved pMJ5913 (13.7kDa) eluting together, 
suggesting that the cleaved LeuR region of RGNEF tends to associate with itself and/or the 
uncleaved pMJ5913 to create soluble oligomers, high-order polymers or aggregates (Figure 8). 
Samples taken from the second peak display cleaved 6xHis-MBP (40.4 kDa), and samples from 
the third peak display TEV protease (27.9kDa) (Figure 8). There were no further peaks isolating 
cleaved pMJ5913 protein, further corroborating the idea that monomeric pMJ5913 lacking the 
fusion tag tends to associate with other monomeric units of cleaved or uncleaved pMJ5913 to 





Figure 8 A-B. Attempted isolation of RGNEF94-219 using SEC. Chromatograph is displayed in (A). Samples 
from peak 1 were mainly comprised of uncleaved pMJ5913, with a small amount of RGNEF94-219 (13.9kDa) 
seen between 11 and 17kDa. Peak 2 displayed cleaved 6xHis-MBP tag (40.2kDa), and peak 3 displayed 
TEV protease (27.9kDa) (B).  
 
3.2.3 Purification of pMJ5804 
Due to the persistently low TEV cleavage efficacy and difficulty isolating cleaved 
RGNEF protein when purifying constructs expressed in pDEST566, it was decided to express 
and purify a pDEST527 construct. While the RGNEF94-219 construct expressed in pDEST527 
(pMJ5804) was relatively less soluble than in pDEST566 (pMJ5913), the use of the pDEST527 
expression plasmid mitigated removal of the 6xHis-MBP tag following purification. Despite the 
lower solubility, it was hoped that growth of a large-scale culture would result in the recovery of 
sufficient untagged protein to perform downstream biophysical analyses. The ORF molecular 
weight of pMJ5804 was 17.2kDa.  
B 
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Following culture growth, 7g of cell pellet were harvested and resuspended in 70mL of 
Ni-A buffer, lysed via French Press cell, and centrifuged to isolate soluble and insoluble lysates. 
60mL of soluble lysate was recovered and pumped onto a 5mL HiTrap HP column (Cytiva Life 
Sciences, United States) Ni-IMAC column at 0.5mL/min at room temperature. Unlike previous 
purifications, a 5% isocratic increase in Ni-B buffer used performed up to 15% Ni-B (45mM 
imidazole) to isolate the concentration of imidazole more accurately at which different products 
eluted. A static 15% Ni-B wash was performed followed by a final elution at 100% Ni-B 
(300mM imidazole). Peak UV absorption during the 100% Ni-B elution reached 280mAu, 
significantly less than elution UV readings from previous purifications. 15mL of 100% elution 
protein was collected with a concentration of 0.593 mg/mL. SDS-PAGE analysis of samples 
taken throughout the purification process display no distinct single band characteristic of induced 
protein expression (Figure 9A). Western Blot was performed on the SDS-PAGE gel, using 
primary anti-His and secondary His-anti-alkaline phosphatase antibodies revealing possibly three 
separate populations of pMJ5804: monomeric (17.2kDa), trimeric (51.6kDa), and tetrameric 
(68.8kDa) (Figure 9A). To confirm this was the protein of interest, a second SDS-PAGE and 
Western Blot analysis was performed comparing uninduced lysates and induced lysates (Figure 
9B). Western Blot revealed proper induction of pMJ5804, though only at a molecular weight 
corresponding to monomeric protein in both soluble and insoluble fractions (Figure 9B). This 




Figure 9 A-B. SDS-PAGE and Western Blot of Ni-IMAC purification samples of pMJ5804. pMJ5804 
was induced at low levels, appearing in three species during 100% Ni-B elution. The green arrow 
indicates the expected location of monomeric pMJ5804, while the blue arrow indicates trimeric pMJ5804, 





 The distinct and disperse molecular weights of each species suggested that they may be 
able to be separated using SEC. 4mL of elution protein was injected onto HiPrep 16/60 
Sephracryl S-300HR (Cytiva Life Sciences, United States) equilibrated with 500mM NaCl, 
20mM Tris HCl pH 8.0 at 1.0mL/min. UV analysis throughout the SEC displayed two 
polydisperse peaks with consistently low mAu reading, indicating poor resolution of the sample. 
Most likely this was due to low sample concentration. SDS-PAGE analysis of samples taken 
during chromatography showed that the larger pMJ5804 species, including predicted trimer and 
tetramer, were eluted throughout the SEC process indicating that they may be forming soluble 
aggregates (Figure 10). Monomeric pMJ5804 was present in the 100% elution but did not appear 
on the SDS-PAGE gel. As such, a second purification with a larger 2L culture to obtain a higher 
100% elution yield and alleviate the poor resolution during SEC was executed.  
  
Figure 10. SDS-PAGE of samples taken from SEC of pMJ5813 attempting to separate monomeric (green 
arrow), trimeric (blue arrow), and tetrameric (orange arrow) species. All pMJ5813 species appeared to 
elute together in peak 1, suggesting the formation of soluble aggregates. 
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 A 2L culture of pMJ5804 was then grown and cells harvested. 13g of cell pellet were 
resuspended in 130mL of Ni-A and lysed via French Press cell. 130mL of soluble lysate was 
recovered and pumped onto a 5mL HiTrap HP column (Cytiva Life Sciences, United States) at 
0.5mL/min at room temperature. A 5% isocratic increase in Ni-B buffer was used up to 15% Ni-
B (45mM imidazole). A static 15% Ni-B wash was performed followed by a 70% Ni-B wash to 
try and flush out less tightly bound pMJ5804 species and obtain a more homogenous 100% 
elution. Peak UV reading reached ~500mAu during the 70% wash. A final elution at 100% Ni-B 
(300mM imidazole) was performed, displaying a shorter and broader UV peak of ~150mAu. 
10mL of 70% wash protein was collected with a concentration of 0.472 mg/mL. 30mL of 100% 
elution protein was collected at a concentration of 0.199mg/mL. SDS-PAGE analysis of samples 
taken from the purification process display a greater heterogeneous population from the 70% 
wash, compared to a more homogenous population within the 100% elution of a protein species 
with MW corresponding to trimeric pMJ5804 (Figure 11A). However, protein eluted during the 
100% elution was less than half the concentration of the 70% wash protein and less visible on the 
SDS-PAGE gel. Western Blot was then performed on samples taken during purification to 
confirm the identity of elutants. Visual analysis of the Western Blot confirmed a much more 
heterogenous mixture of 6xHis-tagged protein within the 70% wash. Most likely, the strongly 
stained bands were species of pMJ5804 in transient oligomeric states, again corroborating 
previous results indicating that RGNEF LeuR constructs tend to self-associate and are not stable 
monomers in solution (Figure 11B). Visual analysis of the 100% elution samples showed a weak 
presence of trimeric and tetrameric pMJ5804, though at minimal concentrations (Figure 11B). A 
strong band also occurred at 25kDa, which did not correspond to the MW of pMJ5804 nor any of 
its oligomeric states. A strong band at this MW also eluted early in the second purification 
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(Figure 11A), as well as in other purifications done in the lab. The strength of this band could 
likely be attributed to the relatively larger culture size (2L). For these reasons, it was determined 
that this band was just a cellular contaminant. Due to the heterogeneity and difficulty obtaining 
workable concentrations of single species of pMJ5804, we moved to purify a new construct in 
pDEST566.   
 
Figure 11 A-B. Purification of 2L cultured pMJ5804 (A) and Western Blot (B). Tetrameric (orange 
arrow) and trimeric (blue arrow) could be readily seen in the SDS-PAGE gel (A), however monomeric 
pMJ5804 was more elusive. All three could be identified in the Western Blot (B). The heterogenous 
nature and low purification concentration prompted dismissal of pMJ5804. 
 
3.2.4 Purification of pMJ5899 
Results from the purification of pMJ5804 suggested that the absence of the 6xHis-MBP 
fusion tag allowed N-terminal RGNEF to self-associate and form different oligomeric species. 
The presence of the fusion tag seemed to prevent this during earlier purifications of pMJ5897 
and pMJ5913. Considering this, it was decided to purify pMJ5899 (74.59kDa) which contained 
RGNEF1-275 (30.3kDa) and the 6xHis-MBP tag (40.2kDa). This construct specifically showed 
A B 
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high solubility during initial screening and truncations with similar domains were often used in 
RGNEF functional studies to analyze the role of the N-terminal domain in vivo51.Additionally, 
RGNEF1-275 was small enough to be differentiated from the fusion tag should TEV cleavage be 
successful.  
 A 1L culture of pMJ5899 was grown and 5g of cell pellet were harvest and resuspended 
in 50mL of Ni-A buffer and lysed via French Press cell. During lysis, a mechanical dysfunction 
in the French Press cell caused entry of air into the cell and frothing of ~20mL of cell lysate 
before the entire sample was visibly lysed. The cell lysate was mixed with an additional 30mL of 
Ni-A buffer for a total volume of 80mL to help maintain protein solubility and centrifuged to 
isolate soluble and insoluble lysates. 65mL of soluble lysate was recovered and pumped onto a 
5mL HiTrap HP column (Cytiva Life Sciences, United States) at 0.5mL/min at room 
temperature. A gradient wash of the column from 0-15% Ni-B (0-45mM imidazole) was used for 
the removal of impurities, followed by a static 15% Ni-B wash. Elution of pMJ5899 was 
performed at 100% Ni-B (300mM imidazole) which reached a sharp peak UV absorption of 
1600mAu (the maximum reading), decreasing rapidly. The sharp peak and rapid decline were 
most likely due to decreased cell lysis and protein recovery during French Press cell lysis. A total 
of 15mL of elution protein was recovered. The first 6mL of protein had a concentration of 
0.33mg/mL and final 9 mL a concentration of 0.99mg/mL. SDS-PAGE analysis of samples taken 
throughout the purification process confirmed a highly induced, soluble protein which eluted at 
high levels during administration of 100% Ni-B buffer and ran at approximately 75kDa, visually 
confirming the induction and purification of 74.59 kDa pMJ5899 (Figure 12). A 4mL samples of 
0.99mg/mL protein was taken and concentrated using a Slide-A-Lyzer MINI Dialysis Units 30 
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000 MWCO centrifugation concentrator (Thermo Scientific, United States) to 2mL at 
2.05mg/mL.   
 
Figure 12. SDS-PAGE of Ni-IMAC purification samples of pMJ5899. pMJ5899 was highly induced and 
appeared at high levels during 100% Ni-B elution. The green arrow indicates location of pMJ5899. 
 
For further biophysical analysis, it was hoped removal of the fusion tag would be 
possible. Eluted pMJ5899 was buffer exchanged into 200mM KCl, 50mM Tris HCl pH 8.0, and 
0.5mM EDTA using a HiPrep 26/10 Desalting column (Cytiva Life Sciences, United States), and 
recovered 15mL at a concentration of 0.6mg/mL. BME was added following buffer exchange for 
a final concentration of 1mM. Similar to the TEV assay performed on pMJ5913, five different 
reaction conditions (15:1, 10:1, 8:1, 4:1, 2:1) of 50PL were set up and left for two different time 
periods of 24h and 48h at 4qC. This was shorter than the previous TEV reaction assay for 
pMJ5913, which incubated for 48h and 72h, as there was minimal visible difference in reaction 
efficacy between the two durations. SDS-PAGE analysis of samples taken from each condition 
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display approximately 50% cleavage efficacy across all conditions, with no visible correlation 
between TEV concentration and cleavage efficacy and a slight visible increase in efficacy when 
left for 48h as opposed to 24h (Figure 13A-B). This influenced the decision to move forward 
with a large scale TEV reaction at a 15:1 protein:TEV protease ratio for 48h, followed by reverse 
Ni-IMAC to isolate RGNEF1-275. 11.5mL of 0.6mg/mL pMJ5899 previously buffer exchanged 
was incubated with a 15:1 TEV concentration at 4qC for 48h. The reaction was then buffer 
exchanged using the HiPrep 26/10 Desalting column (Cytiva Life Sciences, United States) into 
Ni-A buffer, recovering 14.5mL of 0.4mg/mL protein. Reverse Ni-IMAC was performed using a 
5mL HiTrap HP column (Cytiva Life Sciences, United States) with a gradient increase from 0-
100% Ni-B buffer (0-300mM imidazole). Properly cleaved RGNEF1-275 from pMJ5899 would 
lack the 6xHis-MBP tag required for binding to resin beads, thus would elute from the column 
during the flow-through stage at 0% Ni-B, resulting in an increase in UV absorption. This 
increase in UV absorption was not seen during the flow-through step, indicating a lack of 
cleaved protein. SDS-PAGE analysis of samples taken during reverse Ni-IMAC confirms this 
with no banding at the MW corresponding to RGNEF1-275 (30.3kDa) in the flow-through (Figure 
13C). Progressing through the purification, samples display heterogenous mixtures of cleaved 
fusion tag, cleaved RGNEF, and a large proportion of uncleaved pMJ5899 towards 100% Ni-B 




Figure 13 A-C. (A) 24h TEV cleavage assay of pMJ5899.  Increased TEV concentration did not 
significantly increase the degree of pMJ5899 cleaved. (B) 48h TEV cleavage assay of pMJ5899. Similar 
results were seen to that of the 48h assay, indicating that increased time did not increase cleavage 
efficacy. (C) A large-scale TEV reaction was set at a 15:1 ratio for 48h and subject to reverse Ni-IMAC to 




MBP (blue arrow). RGNEF1-275 was not recovered in visible amounts in the flow-through, but did elute 
with uncleaved pMJ5899 at higher % Ni-B. 
 
3.3 Biophysical Characteristics of pMJ5899 
3.3.1 Thermal Shift of pMJ5899 
Considering the multiple attempts made with various constructs and techniques to isolate 
cleaved RGNEF from the 6xHis-MBP fusion tag, biophysical analyses had to then be conducted 
in the presence of the tag without any attempted TEV proteolysis. A protocol for purification of 
RGNEF has not yet been described in the literature, notably due to persistent difficulties 
solubilizing the protein; use of the fusion tag allowed us to circumvent this issue. Additionally, 
an increasing number of proteins have been detailed on databases such as the Protein Data Bank 
(PDB) in the presence of fusion tags, influencing our decision to keep the tag on throughout 
analyses. pMJ5899 was chosen to for biophysical analysis due to its relative purity during Ni-
IMAC purification, stability in different buffer solutions during previous work, broad coverage 
of the predicted LeuR domain and similarity to constructs used in recent functional studies51. 
Biophysical analysis of this construct could then help validate previous investigative work on 
RGNEF and help direct future work. To determine conditions for optimal protein stability, two 
PCR thermal shift screens with 96 conditions each (Durham pH Screen (Molecular Dimensions, 
England) and Durham Salt Screen (Molecular Dimensions, England)) were performed. Results 
from this screen guided buffer selection for subsequent SEC-MALS.  
1mL of purified pMJ5899 (1.3mg/mL) in 100% Ni-B buffer was thawed on ice and 1PL 
of SYPRO Orange Protein Stain (Thermo Scientific, United States) added. In a 0.1-96-well plate 
10PL of protein was combined with 10uL of each screen condition. The plate was covered with a 
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clear, optical seal and placed in the QuanStudio5 Real-Time PCR (Applied Biosystems, Ontario, 
Canada) where method temperature began at 12qC and increased at a steady rate of 0.2qC/s until 
60qC was reached. Fluorescence reading from stained protein was used as a measure of total 
stable protein. More stable protein would be able to maintain a higher level of fluorescence at 
higher temperatures, while less stable protein would denature causing a decrease in fluorescence. 
Results from the salt screen display a clear preference of pMJ5899 for ammonium sulfate (green 
circle, Figure 14A), sodium malonate (blue Asterix, Figure 14A), sodium sulfate (gold diamond, 
Figure 14A), magnesium chloride (grey dash, Figure 14A), and sodium citrate tribasic (gold X, 
Figure 14A). In the presence of each of these salts, pJM5899 displayed high levels of stability 
across a range of ionic strengths. Results from the pH screen show the highest levels of pMJ5899 
stability in pH range 5.0-6.0, particularly in the presence of citrate (blue X, Figure 14B), succinic 
acid (yellow diamond, Figure 14B), and malonic acid (grey triangle, Figure 14B). With the 
combined information of the two thermal shift screens, it was decided to use a buffer of 50mM 






Figure 14 A-B. Thermal shift data of pMJ5899 from the Durham Salt Screen (A) (Molecular 
Dimensions, England) and the Durham pH screen (B) (Molecular Dimensions, England).  
 
3.3.2 SEC-MALS of pMJ5899  
To gain insight into the biophysical characteristics of pJM5899, particularly following the 
difficulties isolating individual species of LeuR constructs from other purification by-products, 




fractions subjected to MALS analysis. Initial chromatographic data from SEC appeared to show 
protein eluate beginning towards the end of the column void volume. This was particularly 
interesting as pMJ5899 has a monomeric MW of 74.59kDa, and the resolution of this column 
had a resolution up to 600kDa. The chromatographic data was corroborated by MALS data, 
which showed high levels of UV absorption in these initial fractions coinciding with and 
immediately following the void volume (Figure 15A), as well as SDS-PAGE analysis of SEC 
samples which showed pMJ5899 did in fact elute with and just after the void volume (Figure 
15B). Together, these suggested the pMJ5899 was forming some sort of oligomeric quaternary 
structure, or simply associating into high MW soluble aggregates. In either scenario, the structure 
would be larger than what could be resolved with the column used. To try and gather more 
information, MALS data was used to calculate a theoretical MW of pMJ5899 using UV 
absorption data and the molecular extinction coefficient (pMJ5899 = 1.409(mg/ml)-1cm-1). Based 
on these, the calculated MW of pMJ5899 was 4.586 x 106 g/mol. The evident inaccuracy of this 
calculation is most likely due to the poor resolution of pMJ5899 as it eluted so close to the void 





Figure 15 A-B. (A) MALS data displayed a large peak in UV (red line) absorption approximately 9-
10mL into the SEC-MALS experiment, corresponding with the end of the column void volume. The 
presence of pMJ5899 (green arrow) in these elution fractions was confirmed via SDS-PAGE (B), both 
suggesting that pMJ5899 formed a higher-order structure or soluble aggregate. 
 
3.4 Determining Region of Interaction Between TDP-43 and RGNEF 
 
 SPR analysis was conducted by immobilization of pMJ5899 and use of TDP-431-103CF as 
analyte. Reverse serial dilutions of TDP-431-103CF were used to determine the degree of 
interaction between the two proteins. As analyte binds to the immobilized ligand, an increase in 
PRIU is seen in the experimental chip channel, but not in the reference channel, indicating 
increased occupancy on the chip. The strength of the interaction can be quantified by the 
difference between pre-analyte injection PRIU and post-analyte injection PRIU. Regeneration 
solution is then washed over the chip to remove any analyte, allowing for the next condition to 
be injected. If an interaction occurs, it is expected there will be a concentration dependent 
increase in PRIU as more analyte binds to the immobilized ligand. Analysis of SPR data, done 
B 
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courtesy of Dr. Crystal McLellan, showed a significant increase in PRIU (~7000 PRIU) 
following injection of pMJ5899 over the experimental channel, indicating pMJ5899 had 
successfully bound the chip (Figure 16). As expected, this increase was not seen in the reference 
channel since no pMJ5899 was injected over it. Experimental data did not display a positive 
change in PRIU reading during either the 1.25PM, 2.5PM, or 10PM injections of TDP-431-103CF 
over the experimental channel with immobilized pMJ5899 (Figure 16). As expected, there were 
no significant changes in PRIU readings during analyte injection over the reference channel. 
Taken together, these results suggested that pMJ5899 did associate properly with the 
carboxymethyl dextran via 6xHis-MBP tag, but did not interact with TDP-431-103CF.  
 
Figure 16. SPR data analyzing the interaction between pMJ5899 and TDP-431-103CF. Reference channel is 
represented by the red line, and the experimental channel by the blue line. Injection of TDP-431-103CF in a 





3.5 Purification of C-terminal pMJ5922 
 pMJ5922 was chosen as the first attempted purification of C-terminal domains, 
specifically including a region of the predicted RNA-binding domain within RGNEF1428-1546. 
pMJ5922 was expressed using pDEST566, thereby having a 6xHis-MBP tag, and a total MW of 
58.6kDa (RGNEF1428-1546 = 14.5kDa). A 1L culture of pMJ5899 was grown and 7g of cell pellet 
were harvest. During initial solubility screening, this construct appeared highly soluble 
prompting a division of the cell pellet to avoid supersaturation and precipitation of pMJ5922. 1/3 
of the cell pellet was isolated and resuspended in 40mL of Ni-A buffer and lysed via cell 
disruptor. The following purification technique varied slightly from previous purifications as this 
construct was purified by Junop Lab technician, Kun Zhang. Cell lysate was centrifuged to 
isolate soluble and insoluble fractions. 40mL of soluble lysate was recovered and pumped onto a 
5mL HiTrap HP column (Cytiva Life Sciences, United States) at 1.0mL/min in a 4qC cold room. 
A 5% isocratic increase in Ni-B buffer from 0-15% Ni-B (0-45mM imidazole) wash used to 
wash out contaminants. A static 15% Ni-B wash was performed followed by a final elution at 
70% Ni-B (210mM imidazole). Peak UV absorption during the 70% Ni-B elution reached 
2000mAu. 11mL of eluted protein was collected which precipitated out of solution shortly after, 
most likely due to the extremely high solubility of this construct. The 11mL of protein was 
centrifuged to recover any remaining soluble protein and concentrated, resulting in 4mL of 
purified pMJ5922 at 1.0mg/mL. SDS-PAGE analysis of samples taken throughout the 
purification process confirmed a highly induced protein which eluted at high levels during 
administration of 70% Ni-B buffer and ran just above 50kDa, visually confirming the induction 
and purification of 58.6kDa pMJ922 (Figure 17). 
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Figure 17. SDS-PAGE of Ni-IMAC purification samples of pMJ5922. pMJ5922 was highly induced and 
appeared at high levels during 100% Ni-B elution. The green arrow indicates location of pMJ5922. 
  
3.6 Biophysical Characteristics of pMJ5922 
 Following successful purification of pMJ5922, thermal shift data was gathered to both 
inform on the biochemical preferences of pMJ5922 and influence buffer solution selection in 
future research. Like pMJ5899, both the Durham pH Screen (Molecular Dimensions, England) 
and Durham Salt Screen (Molecular Dimensions, England) were used on pMJ5922 with 
experimental procedure and measurements performed by QuantStudio5 Real-Time PCR 
(Applied Biosystems, Ontario, Canada). 1mL of pMJ5922 (1.0mg/mL) in 100% Ni-B was 
thawed on ice and mixed with 1PL of SYPRO Orange Protein Stain (Thermo Scientific, United 
States). 10PL of stained protein and 10PL of screen condition were mixed in a well of a 0.1mL-
96 well PCR plate and covered with a clear, optical seal. The 96-well plate was placed into the 
qPCR which ran a method beginning at 12qC and increased steadily at a rate of 0.2qC/s until 
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reaching 60qC. Fluorescence measurements were taken throughout as an indicator of protein 
stability. Results from the pH screen display a preference of approximately pH 6.0-7.0 with the 
use of PIPES (light green circle, Figure 18), MES (yellow X, Figure 18), ACES (gold X, Figure 
18), and Bis-Tris (orange dash, Figure 18). A salt screen was completed as well, however results 
were inconclusive and appeared to show that pMJ5922 precipitated at contact with each solution. 
This screen should be repeated in the near future to determine whether the inconclusive results 
were due to human error or high protein instability. With the results of both screens taken into 
consideration, alteration of lysis and running buffers may mitigate difficulties with precipitation 
and increase protein yield during future purifications.  
 
Figure 18. Thermal shift data of pMJ5922 from the Durham pH screen (B) (Molecular Dimensions, 
England). 
3.7 Defining RNA Binding Ability of pMJ5922 
 In order to determine whether the purified RGNEF construct pMJ5922 maintained the 
RNA binding ability characteristic of its domain, an EMSA was run. Purified pMJ5922 
(1.0mg/mL) in 100% Ni-B was thawed on ice and divided into five separate reaction conditions 
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of decreasing molarity. Based on the volume of a 20PL reaction, the maximum molarity of 
pMJ5922 was 14.45PM (condition 1), followed by 10PM, 5PM, 2.5PM, 1.25PM. BSA and 
fluorescent RNA probe were added; any residual volume was filled by a solution of 800mM 
NaCl, 20mM Tris-HCl pH 8.0 to maintain salt and pH across all conditions. Reactions were 
incubated on ice for 15 minutes and run on a 10% native PAGE (Figure 19). Analysis of the gel 
showed a concentration dependent increase in RNA binding. At 1.25PM and 2.5PM a visibly 
higher amount of protein and RNA had migrated to the bottom of the gel with a small amount of 
shifted protein/RNA complex towards the middle of the gel (Figure 19). At 10PM and 14.45PM 
there was both a decrease in banding at the bottom of the gel and an increase in the density of 
shifted protein/RNA complex, which occurred closer to running wells indicated a concentration 
dependent increase in complex size (Figure 19).  
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Figure 19. 10% native-PAGE of pMJ5922 EMSA. Green arrows point to shifted bands, which increase in 
size in a concentration dependent manner, indicating purified pMJ5922 does bind RNA.  
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Chapter 4 – Discussion 
4.1 Predictive Tools Aid in the Purification of Difficult Proteins 
 Prior to this research, RGNEF had been touted as a particularly problematic protein to 
work with due to difficulties cloning, expressing, and purifying it. To date, there had not been a 
published protocol detailing successful purification of FL-RGNEF nor any truncated constructs. 
With this in mind, we believed the most likely way to be able to purify any part of RGNEF 
would be to first run it through a structure prediction tool and homology modeller. By doing so, 
we were able to “analyze” protein structure without having to first purify the protein. Phyre2, an 
online software used for structure prediction and homology modelling, was able to analyze the 
sequence of FL-RGNEF and predict the probability of a given amino acid populating an 
organized or disorganized region of the protein, allowing us to design construct boundaries 
selectively excluding regions predicted to be highly disorganized54. Additionally, the homology 
modelling feature allowed us to compare the sequence of FL-RGNEF to that of other similar 
proteins and analyze their domain boundaries to influence that of our constructs. This proved to 
be quite useful, as in this study we were able to successfully purify five RGNEF constructs, with 
four distinct domain boundaries. In fact, the power of this software is highly utilized in structural 
biology literature, having been cited 2,959 times since its publication in 2015 as of August 22, 
2021.  
 In the last year, a new online software has become available with even stronger predictive 
measures for protein structure, called AlphaFold57. More recently, an updated AlphaFold2 was 
released58. Using AI technology, AlphaFold combines the thermodynamics of physical 
interaction and homology modelling within a trained neural network to create a highly accurate 
predictive tool58. Not only does this technology validate our method of using structure prediction 
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to influence construct boundaries when cloning, expressing, and purifying select domains or 
regions of a protein, it also assists with the bottleneck of structural biology58. Researchers may 
no longer need to spend months or years attempting to purify and crystallize or use spectroscopic 
techniques on numerous variations of similar protein constructs to determine domain structure 
and implications for biological interactions. By providing researchers with a strong predictive 
tool like AlphaFold, protein structure can be analyzed prior to cloning, expression, and 
purification, allowing researchers to determine their area of interest for a given biological 
interaction. Additionally, access to visual models of tertiary protein structure will assist 
researchers in predicting the hydrophilicity or hydrophobicity of a given protein region based on 
location in the FL structure, providing the opportunity to adjust construct boundaries, cloning 
method, or expression method as needed. The implications for this technology are wide reaching 
– pathway elucidation, disease mechanism, and pharmaceutical targeting, to name very few, may 
all benefit from tools such as AlphaFold. While this technology does not entirely replace the 
need for benchtop lab work, it does assist with and help streamline the process, allowing 
benchtop protein purification and structural characterization to become a form of real-life 
validation for AI technology.  
4.2 RGNEF LeuR Tends to Form Quaternary Structures 
 A significant portion of time in this study was spent trying to isolate a single, untagged 
species of RGNEF LeuR. Those constructs which were expressed using pDEST566 underwent 
TEV proteolysis and subsequent chromatographic techniques (SEC, reverse Ni-IMAC) 
attempting to isolate cleaved RGNEF protein from uncleaved protein and cleavage by-products. 
pMJ5804, the only construct purified which was expressed using pDEST527, underwent SEC to 
isolate a single species from the various RGNEF oligomers (monomer, trimer, tetramer). In the 
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process, it was shown that TEV cleavage of LeuR constructs was relatively ineffective. TEV is 
often touted as a highly effective protease with the ability to be purified in large quantities, 
function in a broad range of environments, and has a selective cleavage sequence 
(ENLYFQ/G)59. However, across four different RGNEF constructs, the visual efficacy of TEV 
proteolysis never surpassed 50%, even at concentrations which were much higher than the 
standard 15:1 ratio. Approximately 50% of purified RGNEF construct remained in a population 
of uncleaved, lending to two more likely scenarios: 1) the large 6xHis-MBP tag was precluding 
TEV from accessing the cleavage site, or 2) purified RGNEF constructs were forming soluble 
higher-order structures, precluding TEV from accessing the cleavage site.  
Possibility 1 could effectively be ruled out as the dual 6xHis-MBP fusion tag is often 
used in place of the single 6xHis-tag for less soluble proteins; while the cleavage efficacy of 
TEV protease on the dual 6xHis-MBP tag is slightly lower than on the single 6xHis-tag, TEV 
protease is able to process ~90% of a given tagged protein population60. Possibility 2, that 
purified RGNEF constructs were forming higher-order structures and obstructing the TEV 
cleavage site, was corroborated by findings during the purification of pMJ5804 and SEC-MALS 
data of pMJ5899. Plasmid pMJ5804 was the only construct to be purified without the dual 
6xHis-MBP tag, rather using the single 6xHis-tag. As previously mentioned, the benefit of using 
the dual tag is the capacity of MBP to pull an otherwise insoluble protein into solution. However, 
the large MW of MBP can cause issues with downstream structure analysis, prompting many to 
remove the tag with TEV protease. In the case of pMJ5804, the absence of MBP allowed us to 
examine the behaviour of RGNEF94-219 in solution without the influence of a large, solubility 
inducing tag. SDS-PAGE analysis of eluate protein showed no distinct, strongly induced band 
that is typically characteristic, prompting anti-6xHis-AP Western Blot of the gel. Visual analysis 
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of the blot using AP displayed 6xHis-tagged protein at MW corresponding to that of a pMJ5804 
monomer, trimer, and tetramer, thought the amount of tagged monomer was quite low. A second 
SDS-PAGE gel was run using whole-cell lysate samples which had been centrifuged to separate 
soluble and insoluble fractions; following Western Blot, both samples displayed only tagged 
protein at the MW of a pMJ5804 monomer. This can be rationalized by considering the relative 
concentrations of pMJ5804 prior to and following Ni-IMAC purification. A relatively low 
concentration of pMJ5804 is present within the entire soluble lysate fraction, but following 
binding of pMJ5804 within the Ni column and elution, there is a relatively higher concentration. 
This increase, along with the known instability of RGNEF, encouraged previously monomeric 
pMJ5804 to associate and form the larger complexes seen in the Ni-IMAC Western Blot. The 
same could be said for pMJ5897, 5913, and 5899, pushing them to form higher-order soluble 
aggregates once purified, preventing TEV cleavage, but appearing as monomers in SDS-PAGE 
following the addition of SDS dye with 5% BME and boiling. This theory of soluble aggregate 
formation was further corroborated with SEC-MALS analysis of pMJ5899. Elution of pMJ5899 
during SEC-MALS occurred immediately following the void volume of the SEC column, which 
had a resolution up to 660kDa, significantly larger than 74.59kDa pMJ5899.  
With the introduction of AlphaFold, we were able to analyze the structure of RGNEF 
virtually to determine the plausibility of oligomerization (entry Q8N1W1)58. Expected position 
error of a given residue along RGNEF1-275 was almost entirely scored as “confident” (90 > 
AlphaFold confidence > 70) or “very high” (AlphaFold confidence > 90). Residues 1-94 were 
predicted to be comprised of a seven-strand beta-sheet which transitioned into alpha-helices from 
residues 95-219. Residues 229-254 occupy a triple-strand beta-sheet, followed by a small alpha 
helix from residues 261-284. Residues 285-395 were classified as low confidence and appears to 
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occupy a disorganized loop along the exterior of the protein. Given the highly organized 
structure of the predicted LeuR domain, and the density of Leu residues, it is very much 
plausible that purification fostered quaternary structure associations. This is particularly notable 
in the region of RGNEF94-219 which may have created coiled coils (24% Leu). A similar theory 
has been proposed by Kunijthapatham et al.61 who suggested that “intrinsically stable alpha-
helices can associate into aggregates with only coarse coiled-coil symmetry” and may present a 
mechanism for pathogenic protein aggregation, such as in ALS. 
4.3 Purified pMJ5899 Does Not Bind TDP-43 in vitro  
 SPR experiment data shown no direct interaction between pMJ5899, which encompassed 
a large portion of the LeuR domain predicted to interact with TDP-43, and TDP-431-103CF. 
However, previous research has pointed to a direct interaction between the two proteins via 
colocalization and coimmunoprecipitation53. There are some possible explanations for the 
divergent findings. One possibility is that the interaction between RGNEF and TDP-43 requires 
the presence of at least one other biological molecule in order to form an indirect interaction that 
leads to the recruitment of RGNEF to TDP-43+ NCIs. Currently, there is no evidence published 
to suggest this, however, there is also none which refutes it.  
A second reason as to why we did not observe an interaction between pMJ5899 and 
TDP-431-103CF could be the structure of RGNEF itself. As described above, NI-IMAC, SEC, and 
SEC-MALS data all demonstrated that LeuR RGNEF tends to form oligomeric quaternary 
structures when purified due to high structural organization (predicted by AlphaFold). Though 
pMJ5899 appeared to be monomeric during SDS-PAGE analysis, leading us to believe it was 
monomeric for the use of SPR, observation of pMJ5899 at monomeric MW may have been due 
to the addition of SDS-dye + 5% BME and subsequent boiling. Organization of pMJ5899 into 
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higher order structures may have then precluded the binding site for TDP-431-103CF. For this 
reason, a native-PAGE should be run in the near future to determine whether purified pMJ5899 
exists as a monomer in solution.  
The binding of TDP-431-103CF to RGNEF may also be dependent on the presence of 
additional regions of either protein. Particularly in the case of RGNEF, a set of three parallel 
alpha helices spanning RGNEF1200-1411 (as predicted by AlphaFold) run just above the organized 
LeuR predicted domain. Additionally, there is large alpha helix spanning RGNEF1430-1529 which 
runs directly behind and on either side of the LeuR. The ability of the LeuR region to bind TDP-
43 may hinge on the presence of either of these structures. The necessary structures for binding 
RGNEF may also not be encompassed in the TDP-431-103CF construct. Purification of FL-TDP-43 
is a lengthy process, requiring refolding of the protein following purification or mutation of 
tryptophan residues to alanine, but may be required in order to observe this interaction62,63. 
Related, the TDP-431-103CF was a cysteine-free construct previously used optimized for 
purification and crystallization, however cysteine residues have a large influence on protein 
structure and their presence may be necessary for proper conformation for RGNEF binding.  
4.4 Purified pMJ5922 Retains Moderate RNA-Binding Capacity  
 The predicted RBD of RGNEF has previously been shown to exercise binding of target 
RNA in vivo through use of split ubiquitin systems54. In this study, EMSA was used to determine 
whether a truncation of the RBD, pMJ5922, would continue to bind RNA ex-vivo following 
purification. Given the presence of the 6xHis-MBP tag on pMJ5922 as well as the small size of 
the inserted RGNEF construct (amino acids 1428-1546), it would not have been surprising if 
there had not been evident RNA binding. However, EMSA results demonstrated that pMJ5922 
does in fact bind a 5’-6-FAM poly-U RNA probe in a concentration dependent manner, 
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validating that the RBD can be successfully purified and maintain its domain function without 
the presence of the remainder of the RGNEF protein. Yet, the degree of RNA binding in the 
EMSA experiment was visibly low – less than half of the fluorescent probe bound pMJ922 in 
even the highest protein concentration condition (14.45PM). This could have been due to the 
high levels of salt present in the reaction. pMJ5922 proved fairly unstable in solution following 
protein purification when a large amount of eluate precipitated shortly after collection. This 
occurred again during latter lab work when attempting to dialyze pMJ5922 out of 100% Ni-B 
and into a new buffer. For this reason, we chose to continue the EMSA experiment without 
altering the storage buffer of pMJ5922 but with the consideration that under high salt conditions 
such as Ni-B (800mM NaCl) the electrostatic interaction between protein and nucleic acids can 
be disrupted. The salt concentration could then have been the limiting factor for the low level of 
protein-RNA binding seen. Given the promising EMSA results, a dialysis was attempted into a 
lower salt buffer pH adjusted with the consideration of thermal shift results (300mM NaCl, 
50mM Tris-HCl pH 7.5), but this too precipitated.  
 To increase the degree of RNA binding by the RBD, a greater portion of the RBD or 
other components of RGNEF may need to be expressed as well. pMJ5922 was one of the 
smallest constructs designed in this project, encompassing RGNEF1428-1546. Analysis of the 
AlphaFold structure reveals that this region of the protein is predicted to exist as a single alpha 
helix which runs alongside the highly organized LeuR region, as well as a three-strand alpha 
helical region spanning RGNEF1200-1411. It is possible that the presence of these highly organized 
regions helps with the stability and RNA binding function of the RBD, or that the full extent of 
RNA binding cannot been seen without a larger portion of the RBD. Despite this, results showed 
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that a section of the RGNEF RBD could be successfully purified and was able to maintain the 
same RNA binding function as seen in in vivo functional studies56.  
4.5 Future Directions  
 The work in this project documents the first time that the LeuR and RBD of RGNEF have 
been successfully purified, allowing for the investigation of the TDP-43/LeuR interaction using 
SPR and validation of the RNA binding function in an ex vivo setting. The development of a 
protocol for the purification of both the LeuR and RBD of RGNEF lays the foundation for future 
work examining the nature of the interaction between RGNEF/TDP-43, pathologic implications 
of RGNEF aggregation, and structure of RGNEF.  
To further the work done investigating the interaction between the LeuR and TDP-43, 
future purifications of LeuR constructs should run native-PAGE gels in addition to post-
purification SDS-PAGE gels in order to determine whether or not purified proteins are forming 
higher-order structures. This could be further elucidated by analytical ultracentrifugation 
sedimentation velocity, or SEC-MALS with the use of a broader resolution column. These 
results could influence the interpretation of earlier SPR results, if in fact the TDP-43 binding site 
may have been precluded. Additionally, FL-TDP-43 should be purified and used for the purpose 
of SPR. As mentioned (4.3 Purified pMJ5899 Does Not Bind TDP-43 in-vitro), binding of TDP-
43 to RGNEF may depend on the presence of a larger TDP-43 region.  
Future work on the RBD should look to purify a broader-spanning construct of the RBD 
to analyze whether RNA binding ability increases with the expression of a larger section of the 
domain. Purified constructs should undergo pH and salt thermal shift to determine optimal buffer 
conditions for subsequent work, followed by replication of the ESMA experiment. If possible, 
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ESMA should be performed at a lower salt concentration to optimize the possibility of protein-
nucleic acid interactions.  
Finally, purified RGNEF constructs should be analyzed using structural biology 
techniques such as x-ray crystallography or nuclear magnetic resonance spectroscopy to validate 
the predicted structure now available on AlphaFold. Ideally, constructs purified using the 
pDEST566 vector should have the 6xHis-MBP tag removed to reduce any flexibility 
disorganization which may reduce the ability of pure protein to form crystals; however, if not 
possible, the number of structures uploaded to the PDB with the inclusion of fusion tags has been 
increasing over the past few years and would still aid in the validation of the AlphaFold 
structure. Once validated, both wet lab and virtual techniques could be used to help develop 
therapeutic intervention inhibiting the aggregation of RGNEF, reducing NCI load and 
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